| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Nanomedicine | Oncology | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Nanomedicine | Oncology | ||
phase 3 data readout example | Phase 3 | — | Subscribe to access the data. | Nanomedicine | Oncology |
Recent Updates
Recently added Catalysts
Nanobiotix S.A.$40.07
+1.12 (+2.88%)
D 30Pipeline Score Richly Valued Pharma · Clinical
Market Cap
2.05 B
EPS
-0.57
P/E Ratio
-
Value Trade
1.73 M
-21.57 %
Week
30.73 %
1 Month
58.03 %
3 Month
93.35 %
6 Month
153.93 %
5 Year
125.95 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
119.85 K
52 Week Range
3.81 - 57.14
% held by Insiders
19.6 %
% held by Institutions
0.15 %
Enterprise Value
2.10 B
Total Shares
48.38 M
Short %
0.16 %
Float Shares
38.46 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Nanobiotix S.A.
594Total events
5Upcoming
112Tier-1 (high impact)
2014 – 2028Coverage
Upcoming catalysts 5
Event history 589
Jun 2, 2026
May 26, 2026
▼Equity OfferingCorporate
Closing of global offering including full exercise of underwriters' option, raising approximately $100 million
May 22, 2026
▼Equity OfferingCorporate
Full exercise of overallotment option for global offering, raising $100M gross proceeds
May 21, 2026
▼Equity OfferingCorporate
Suspension of trading for global offering of ADS and ordinary shares
May 20, 2026
May 17, 2026
▲Oral PresentationNBTXR3ApprovedPresentation
Presentation of Part 1 data from CONVERGE study at ESTRO 2026
stage 3 inoperable non-small cell lung cancersource ↗
May 4, 2026
▲Protocol AmendmentNBTXR3ApprovedTrial
FDA acceptance of protocol amendment for NANORAY-312 removing interim analysis and modifying final analysis
locally advanced squamous cell carcinoma of the head and necksource ↗
May 2026
Apr 20, 2026
●Poster PresentationPresentation
Poster #6389: Maximizing systemic LNP-DNA delivery for cancer-activated expression of Immunotherapy agents using Nanoprimer technology at AACR 2026
cancersource ↗
Drug Pipeline Intelligence
D30
Pipeline Score $222M
Pipeline ValueRichly Valued
Valuation Signal1
Drugs Scored0.1x
rNPV / MCap Top 34%
Small Cap (rank 603 of 912)
Percentile RankNanobiotix S.A. faces pipeline headwinds (30/100), with $408M risk-adjusted pipeline value, led by NBTXR3 in Locally-Advanced Non-Small Cell Lung Cancer (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NBTXR3 Unknown | Adult Soft Tissue Sarcoma | Phase 2 | NCT01433068 | 11% | $408M | COMPLETED | 202 | - | - | Feb 1, 2015 | - | Oct 6, 2020 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
JNJ-1900 (NBTXR3) Fast Track | stage 3 inoperable non-small cell lung cancer | Phase 2 | 2026-05-17 | overall response rate: 85.7% (6/7 patients); complete response rate: 57.1% (4/7 patients); disease control rate: 100.0% (7/7 patients) Read More | Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer Read More | |
JNJ-1900 (NBTXR3) Fast Track | stage 3 inoperable non-small cell lung cancer | Phase 2 | 2026-05-17 | overall response rate: 85.7% (6/7 patients); complete response rate: 57.1% (4/7 patients); disease control rate: 100.0% (7/7 patients) Read More | Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer Read More | |
JNJ-1900 (NBTXR3) Fast Track | stage 3 inoperable non-small cell lung cancer | Phase 2 | 2026-05-17 | overall response rate: 85.7% (6/7 patients); complete response rate: 57.1% (4/7 patients); disease control rate: 100.0% (7/7 patients) Read More | Nanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in NBTX
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
NBTX Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
NBTXNanobiotix fait le point sur sa tresorerie et son activite operationnelle pour le premier trimestre 2026
Nanobiotix has reported a successful capital increase of €86.1 million to accelerate its development efforts. The company presented promising data from its Phase 2 study of JNJ-1900 for inoperable stage 3 lung cancer at the ESTRO 2026 conference. Additionally, the FDA has accepted a protocol amendment for the ongoing NANORAY-312 study, allowing for an earlier readout. With €42.1 million in cash reserves, Nanobiotix expects to meet its operational needs through 2029.
Read more →NBTXNanobiotix Provides First Quarter 2026 Operational and Financial Update
Nanobiotix reported a strong operational and financial update for Q1 2026, highlighting a successful €86.1 million follow-on offering. The company presented promising data from the Phase 2 CONVERGE study of JNJ-1900 (NBTXR3) for NSCLC, showing an 85.7% overall response rate. Additionally, the FDA accepted a protocol amendment for the NANORAY-312 study, enhancing the study's design.
Read more →NBTXNanobiotix rejoint l'indice Euronext Tech Leaders
Nanobiotix has announced its inclusion in the Euronext Tech Leaders index, which aims to enhance the visibility of high-growth European tech companies. This recognition reflects the company's advancements in nanotechnology and its commitment to developing innovative therapeutic approaches for cancer and other diseases. The initiative will provide Nanobiotix with increased exposure to international investors and support for long-term growth.
Read more →NBTXNanobiotix Joins the Euronext Tech Leaders Index
Nanobiotix has been included in the Euronext Tech Leaders Index, highlighting its innovative contributions in nanotechnology and medicine. This recognition reflects the company's growth and potential in addressing significant medical needs. CEO Laurent Levy emphasized the importance of physics-based innovation in healthcare. The initiative aims to enhance visibility for leading technology companies in Europe.
Read more →NBTXNANOBIOTIX annonce le règlement-livraison de son offre globale
Nanobiotix has successfully completed its global offering, raising approximately $100 million. The offering included the full exercise of an option by banks to subscribe for additional shares. The company plans to allocate the proceeds to support the development of its therapeutic platforms, including JNJ-1900 and Nanoprimer.
Read more →NBTXNANOBIOTIX Announces Closing of Global Offering
Nanobiotix has successfully closed its global offering, raising approximately $100 million. The offering included the full exercise of the underwriters' option to purchase additional shares. The proceeds will primarily support the advancement of its Nanoprimer platform and other corporate purposes. The company expects these funds will sustain its operations into 2029.
Read more →NBTXNANOBIOTIX Announces Full Exercise of Underwriters’ Over-Allotment Option, Bringing Gross Proceeds of Offering to Approximately $100 Million
Nanobiotix has announced the full exercise of the underwriters' over-allotment option in its global offering, resulting in gross proceeds of about $100 million. The offering includes 33,805 additional American Depositary Shares (ADSs) priced at $38.98 each. The company plans to allocate the funds primarily towards advancing its Nanoprimer platform and other corporate purposes.
Read more →NBTXNANOBIOTIX annonce l’exercice integral de l’option de surallocation, portant le produit de l'offre a 100 millions de dollars
Nanobiotix has announced the full exercise of the over-allotment option in its global offering, resulting in total gross proceeds of around $100 million. The company plans to allocate these funds to advance its therapeutic platforms, including the development of JNJ-1900 (NBTXR3) and Nanoprimer. The offering is set to close on May 26, 2026.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix Announces Pricing of Oversubscribed €85m Global Offering
Nanobiotix has announced the pricing of its oversubscribed €85 million global offering, which includes a public offering of American Depositary Shares (ADSs) and Ordinary Shares. The offering is expected to yield approximately $98.6 million in gross proceeds, aimed at advancing its cancer treatment platforms. The expected closing date for the offering is May 26, 2026.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix annonce la reprise des négociations de ses actions ordinaires sur Euronext Paris
Nanobiotix has announced the resumption of trading for its common shares on Euronext Paris, effective May 21, 2026. This follows a temporary suspension related to a previously announced public offering of American Depositary Shares and other securities. The company aims to confirm allocations to investors and finalize the terms of the global offering.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix Announces Trading Resumption of Its Ordinary Shares on Euronext Paris
Nanobiotix has announced the resumption of trading for its ordinary shares on Euronext Paris. This follows a temporary halt to facilitate a public offering of American Depositary Shares and other securities. The company is focused on innovative, physics-based approaches to cancer treatment and holds numerous patents in the biotechnology field.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix annonce la suspension temporaire du cours de ses actions ordinaires sur Euronext Paris
Nanobiotix has announced a temporary suspension of its ordinary shares on Euronext Paris, effective from 9:00 AM CEST. This decision is part of a previously announced offering that includes American Depositary Shares and other equity instruments aimed at qualified investors. Trading is expected to resume later in the day.
Read more →NBTX▼ -6.9%on this newsshared move
Nanobiotix Announces Temporary Trading Halt of Its Ordinary Shares on Euronext Paris
Nanobiotix has announced a temporary halt in trading of its ordinary shares on Euronext Paris at the company's request. This decision is part of a global offering that includes both U.S. and international offerings. Trading is expected to resume later the same day, allowing for the confirmation of allocations and pricing announcements.
Read more →NBTX▼ -6.6%on this newsshared move
Nanobiotix Announces Launch of Global Follow-On Offering
Nanobiotix has announced a global follow-on offering of approximately €75 million to support its cancer treatment developments. The offering includes American Depositary Shares and Ordinary Shares, targeting qualified investors in Europe and the U.S. The company plans to use the proceeds for its Nanoprimer platform and other corporate purposes. The final terms will be determined after a book-building process.
Read more →NBTX▼ -6.6%on this newsshared move
Nanobiotix annonce le lancement d’une offre globale
Nanobiotix has announced the launch of a global offering aimed at raising approximately €75 million. This offering will consist of American Depositary Shares (ADS) and pre-funded warrants, targeting qualified investors in Europe and the U.S. The company intends to allocate the proceeds towards the advancement of its therapeutic platforms and general corporate purposes. The final terms of the offering will be determined through a book-building process.
Read more →NBTXNanobiotix Announces Presentation of Part 1 Data From a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
Nanobiotix announced positive results from Part 1 of the CONVERGE study, a Phase 2 clinical trial evaluating JNJ-1900 (NBTXR3) in patients with stage 3 inoperable non-small cell lung cancer. The data presented at ESTRO 2026 indicated an overall response rate of 85.7% and a complete response rate of 57.1%. The treatment was found to be feasible and safe, with a 100% disease control rate observed in the study.
Read more →NBTX▼ -11.3%on this news· ran to +21% by day 3
Nanobiotix Announces Protocol Amendment to Ongoing Global Phase 3 Head and Neck Cancer Study
Nanobiotix announced FDA acceptance of a protocol amendment for its NANORAY-312 study, which modifies the final analysis to include fewer events and be conducted sooner. This change could expedite the global registration pathway for JNJ-1900 (NBTXR3) in head and neck cancer, potentially leading to earlier revenue generation. The company expects the modified analysis to read out in the same timeframe as the previous interim analysis.
Read more →NBTX▼ -11.3%on this news· ran to +21% by day 3
NANOBIOTIX ANNONCE UN AMENDEMENT DU PROTOCOLE DE L’ÉTUDE MONDIALE DE PHASE 3 SUR LE CANCER DE LA TÊTE ET DU COU
Nanobiotix announced that the FDA has accepted an amendment to the NANORAY-312 study protocol for JNJ-1900 (NBTXR3) in head and neck cancer. The amendment removes the previously planned interim analysis and modifies the final analysis to include fewer events, potentially allowing for earlier results. This change could expedite the registration pathway for the treatment and enhance revenue opportunities for the company.
Read more →NBTX▼ -5.6%on this news
Nanobiotix Announces New Preclinical Data Supporting Improved Systemic Bioavailability and Reduced Toxicity for LNP-Delivered DNA Immunotherapy After Pre-Treatment With Nanoprimer Technology
Nanobiotix presented new preclinical data at the AACR 2026 meeting, demonstrating that its Nanoprimer technology significantly enhances the systemic bioavailability of lipid nanoparticle-delivered DNA immunotherapy while reducing liver toxicity. The study showed that pre-treatment with Nanoprimer improved therapeutic outcomes by mitigating inflammation and enhancing drug delivery. These findings support further exploration of Nanoprimer in advanced therapeutic applications.
Read more →NBTX▲ +10.4%on this news
NANOBIOTIX Provides Business Update and Reports Full Year 2025 Financial Results
Nanobiotix provided a business update and reported its financial results for the year 2025, highlighting significant advancements in its clinical programs, particularly for JNJ-1900 (NBTXR3). The company achieved €32.6 million in revenue, a notable recovery from the previous year. Despite a net loss of €24.0 million, the company strengthened its financial position and anticipates funding to support operations into early 2028.
Read more →NBTXNANOBIOTIX Announces Presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer
NANOBIOTIX presented initial data from the CONVERGE study at the 2026 European Lung Cancer Conference. This Phase 2 trial evaluates JNJ-1900 (NBTXR3) for stage 3 inoperable non-small cell lung cancer. The results indicate a promising overall response rate of 71.4% and no serious treatment-related adverse events, supporting further development of this novel therapy.
Read more →NBTXNANOBIOTIX to Announce Fourth Quarter and Full Year 2025 Operational and Financial Update on March 31st, 2026
NANOBIOTIX will announce its fourth quarter and full year 2025 financial results on March 31, 2026. A conference call and webcast are scheduled for April 1, 2026, where executives will review results and discuss business activities. The company focuses on innovative cancer treatments using nanoparticle technology.
Read more →NBTXDeclaration de NANOBIOTIX concernant une recente rumeur mediatique
Nanobiotix has addressed recent media rumors regarding a potential takeover of the company. They assert that there is no intention or process for such an acquisition. Additionally, the company has pointed out factual inaccuracies in the media reports that contradict their latest public information.
Read more →NBTXNANOBIOTIX Statement Regarding Recent Media Speculation
Nanobiotix has issued a statement addressing recent media speculation about a potential takeover. The company asserts that there is no intention to acquire control and has pointed out inaccuracies in the media reports. This clarification aims to reassure stakeholders about the company's current status and intentions.
Read more →NBTX▲ +6.6%on this news· ran to +20% by day 1
NANOBIOTIX to Participate in Investor Conferences in March 2026
NANOBIOTIX announced its participation in several investor conferences in March 2026, including the TD Cowen's Health Care Conference and the UBS Biotech Summit. Key executives, including CEO Laurent Levy, will present at these events, highlighting the company's pioneering work in nanotherapeutics for cancer treatment. This engagement reflects the company's commitment to expanding treatment possibilities.
Read more →NBTXNANOBIOTIX to Join CAC Mid 60 and SBF 120 Indices on Euronext Paris
Nanobiotix has been admitted to the CAC Mid 60 and SBF 120 indices on Euronext Paris, effective December 19, 2025. This inclusion is expected to enhance the company's visibility among institutional investors and strengthen its presence in European markets. CEO Laurent Levy expressed confidence in the company's long-term strategy and the potential of its nanotherapeutic solutions.
Read more →NBTXNANOBIOTIX va intégrer les indices CAC Mid 60 et SBF 120 d’Euronext Paris
Nanobiotix has been admitted to the CAC Mid 60 and SBF 120 indices of Euronext Paris, effective December 19, 2025. This inclusion is anticipated to increase the company's visibility among institutional investors and strengthen its presence in European markets. Laurent Levy, co-founder, expressed that this reflects the financial markets' confidence in their long-term strategy and innovative therapeutic solutions.
Read more →NBTXPDMR NOTIFICATIONS exhibit991december1st 2025DD1072320 FR0011341205 - DD190222 01 d cembre 2025 INFORMATION D claration individuelle relative aux op rations des personnes mentionn es l'article L.621-18-2 du Code mon tair
Nanobiotix's chairman, Laurent Levy, has conducted a significant transaction involving the sale of shares, totaling 295,000 shares at a price of 17.2794 Euro each. This sale has enabled the complete reimbursement of bank loans contracted to finance stock option exercises, thereby terminating the pledge on remaining owned shares. The notification emphasizes that the transaction was made under the responsibility of the declarant without prior control from the AMF.
Read more →NBTX▲ +5.1%on this news
Nanobiotix Provides Third Quarter 2025 Operational and Financial Update Along With 2026 Clinical Outlook
Nanobiotix provided an operational and financial update for Q3 2025, highlighting a successful royalty financing agreement valued at up to $71 million, enabling the establishment of a self-sustained growth foundation. Significant clinical advancements were noted for JNJ-1900 (NBTXR3), including Phase 1 study data for esophageal cancer. The company plans to continue developing its internal pipeline and external collaborations, especially with its Curadigm Nanoprimer program. An operational cash position of €20.4 million was reported, which is expected to enhance financial visibility through early 2028.
Read more →NBTX▼ -6.1%on this news
NANOBIOTIX Announces Curadigm Nanoprimer Platform Advancements With Updated Plans for Internal Pipeline Development and External Collaborations
Nanobiotix has announced significant advancements in its Curadigm Nanoprimer platform, which is designed to enhance the delivery of therapeutic agents in cancer treatment. Four new patent applications have been filed to strengthen the intellectual property foundation, while promising pre-clinical data were presented at the 2025 Partnership Opportunities in Drug Delivery conference. The company is also progressing with external collaborations supported by various material transfer agreements. Nanobiotix aims to establish a proprietary pipeline of Nanoprimer products to target challenges in drug delivery.
Read more →NBTXNANOBIOTIX to Participate in Jefferies London Healthcare Conference
Nanobiotix will participate in the Jefferies London Healthcare Conference on November 17, 2025. CEO Laurent Levy and CFO Bart van Rhijn will present in a fireside chat, which will be webcast live. The company focuses on pioneering nanotherapeutic approaches for cancer treatment and has a strong patent portfolio.
Read more →NBTXNANOBIOTIX participera à la conférence Jefferies London Healthcare
Nanobiotix will participate in the Jefferies London Healthcare Conference on November 17, 2025. Key executives, including co-founder Laurent Levy, will engage in a fireside chat. The presentation will be broadcast live, with a replay available afterward. Nanobiotix focuses on innovative therapeutic approaches using nanoparticles for cancer treatment.
Read more →NBTX▲ +9.2%on this news
NANOBIOTIX to Participate in Investor Conferences the Week of November 10th
Nanobiotix will participate in several investor conferences during the week of November 10, 2025. Key presentations will be made by CEO Laurent Levy and CFO Bart van Rhijn at conferences in Florida, Massachusetts, and New York. The events will be webcasted live, allowing broader access to their discussions on nanotherapeutic innovations.
Read more →NBTX▲ +9.2%on this news
NANOBIOTIX participera à des conférences investisseurs la semaine du 10 novembre
Nanobiotix will participate in several investor conferences during the week of November 10, 2025. Key executives, including Bart van Rhijn and Laurent Levy, will represent the company at events such as the UBS Global Healthcare Conference and the Stifel Healthcare Conference. These presentations aim to showcase Nanobiotix's innovative approaches in biotechnology.
Read more →NBTX▲ +13.2%on this newsshared move
NANOBIOTIX Announces Strategic Royalty Monetization Agreement With Healthcare Royalty for up to $71 Million and Extends Cash Runway Toward Long-Term Growth
Nanobiotix has entered a royalty-based financing agreement with HealthCare Royalty, securing up to $71 million to support its growth and development of nanotherapeutics. This funding aims to enhance the company's financial sustainability and advance its innovative cancer treatment platforms. The agreement extends the cash runway into early 2028, contingent on closing the deal.
Read more →NBTX▲ +13.2%on this newsshared move
NANOBIOTIX annonce un accord stratégique avec HealthCare Royalty pour un montant maximum de 71 millions de dollars et prolonge ainsi son horizon de trésorerie pour une croissance durable
Nanobiotix has entered into a strategic royalty financing agreement with HealthCare Royalty, potentially worth up to $71 million. This funding aims to enhance the company's financial stability and support the development of its nanoparticle therapies. The agreement is expected to extend Nanobiotix's cash runway until early 2028, facilitating further clinical advancements.
Read more →NBTXNANOBIOTIX Announces Updates to JNJ-1900 (NBTXR3) Clinical Program Following Transfer of Ongoing Phase 3 Head and Neck Cancer Trial Sponsorship and Operational Control
NANOBIOTIX has transferred the sponsorship and operational control of its Phase 3 trial for JNJ-1900 (NBTXR3) to Johnson & Johnson. The interim data from the NANORAY-312 study is expected to be reported in the first half of 2027. The company continues to collaborate with J&J and The University of Texas MD Anderson Cancer Center for further development of JNJ-1900.
Read more →NBTXNANOBIOTIX annonce des mises à jour sur le programme clinique de JNJ-1900 (NBTXR3) à la suite du transfert de sponsorship et du contrôle opérationnel de l’essai de Phase 3 en cours dans le cancer de la tête et du cou
Nanobiotix has announced updates on its clinical program for JNJ-1900 (NBTXR3) following the transfer of sponsorship and operational control of the ongoing Phase 3 trial in head and neck cancer to Johnson & Johnson. The interim analysis for the trial is expected to be communicated after the required number of events is observed, anticipated in the first half of 2027. Nanobiotix will continue to provide updates on the development of JNJ-1900 in collaboration with J&J and the MD Anderson Cancer Center.
Read more →NBTXNANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
NANOBIOTIX announced promising preliminary data from a Phase 1 study evaluating JNJ-1900 (NBTXR3) combined with chemoradiation in patients with locally advanced adenocarcinoma of the esophagus. The treatment showed an 85% disease control rate and a 69% objective response rate, including complete responses in six patients. Treatment was well-tolerated with manageable adverse events, and the study is ongoing with plans for further recruitment. The findings, presented at the ASTRO annual meeting, suggest that JNJ-1900 may improve local tumor control and reduce the need for invasive surgical procedures.
Read more →NBTXNANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Nanobiotix recently provided a business update alongside its financial results for the first half of 2025. The company reported a significant increase in revenue, driven by progress in its clinical development program, particularly with JNJ-1900 (NBTXR3). However, the report also highlighted a net loss and potential concerns regarding its ongoing financial viability due to a decrease in cash reserves. The company is pursuing options for non-dilutive financing to enhance its cash runway and ensure continued operation.
Read more →NBTXNANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
NANOBIOTIX announced new results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) in combination with immune checkpoint inhibitors for patients with primary cutaneous melanoma resistant to anti-PD-1 therapies. The study reported a favorable safety profile and early efficacy signals, with an objective response rate of 47.4% and a median overall survival of 14.6 months. Researchers concluded that these findings warrant further investigations in randomized clinical trials, seeing potential in JNJ-1900 as a new treatment option for this challenging patient population.
Read more →NBTX▼ -5.8%on this news
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Nanobiotix announced its participation in the H.C. Wainwright 27th Annual Global Investment Conference, scheduled for September 9, 2025. Company executives, including CEO Laurent Levy, will engage in a fireside chat that will be streamed live. This event showcases the company's commitment to innovative cancer treatments and increases visibility among potential investors. Established in 2003, Nanobiotix focuses on pioneering nanoparticle-based therapies and holds over 25 patent families in the field.
Read more →NBTXNANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
Nanobiotix has announced significant advancements for its product, JNJ-1900 (NBTXR3), including its reclassification from a medical device to a medicinal product by major European health authorities, aligning it with regulatory status in the US. Additionally, the company has filed a new composition of matter patent to bolster its intellectual property protections. This reclassification and patent filing are part of Nanobiotix's strategy to establish JNJ-1900 as a potential first-in-class radioenhancer, currently being evaluated in various clinical trials, including a pivotal Phase 3 trial for head and neck cancer.
Read more →NBTXK 1 exhibit9916kfiling-july2.htm 6-K exhibit9916kfiling-july2 2025DD1045711 FR0011341205 - DD188343 02 juillet 2025 INFORMATION D claration individuelle relative aux op rations des personnes mentionn es l'article L.621-1
Nanobiotix has issued new notifications regarding transactions by key executives under Article L.621-18-2 of the Monetary and Financial Code. The notifications, received on July 2, 2025, detail free share allocations to multiple executive officers, including the CEO and Chief Financial Officer. These transactions occurred on June 27, 2025, with the prices set at zero euros. The report clarifies that the AMF did not control this notification, and it solely reflects the declarant's responsibility.
Read more →NBTX▲ +5.4%on this news
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Nanobiotix, a late-stage biotechnology company, announced its participation in the Jefferies Global Healthcare Investor Conference on June 5, 2025. The event, which will feature a webcast of the presentation, offers the company a platform to discuss its pioneering nanoparticle-based cancer treatments. This participation is expected to enhance Nanobiotix's visibility among potential investors and stakeholders in the healthcare sector.
Read more →NBTXAMF ATTESTATION exhibit991may272025 2025DD1039719 FR0011341205 - DD187665 26 mai 2025 INFORMATION D claration individuelle relative aux op rations des personnes mentionn es l'article L.621-18-2 du Code mon taire et finan
The article details several stock acquisitions by Nanobiotix, with transactions occurring on May 21, 22, and 23, 2025, on Euronext Paris. Each transaction reports specific acquisition prices and volumes, highlighting investment activity. The notice serves as a declaration under applicable financial regulations, asserting the responsibility of the declarant and compliance with relevant legal frameworks. This ongoing trading indicates a proactive approach to financial management.
Read more →NBTXAMF DECLARATION exhibit991may272025-part 2025DD1039917 FR0011341205 - DD187700 27 mai 2025 INFORMATION D claration individuelle relative aux op rations des personnes mentionn es l'article L.621-18-2 du Code mon taire et
On May 26, 2025, Bartholomeus van Rhijn conducted an acquisition of 10,780 shares of Nanobiotix at a unit price of 3.4145 euros per share on Euronext Paris. This transaction was reported under the applicable regulations without prior review by the AMF. The notification indicates the responsibility lies solely with the declarant. The issuer of the shares is Nanobiotix, identified by LEI 969500667RSYIH8YL895.
Read more →NBTXNanobiotix Provides First Quarter 2025 Operational and Financial Update
Nanobiotix announced its operational and financial update for the first quarter of 2025, highlighting the successful dosing of the first patient in the Phase 2 CONVERGE study for patients with unresectable stage 3 non-small cell lung cancer. The company also reported encouraging results from various studies involving JNJ-1900, including data presented at the European Lung Cancer Conference. Furthermore, an amendment to the global licensing agreement has extended Nanobiotix's cash runway through mid-2026 while reducing operational costs. Overall, the update reflects positive advancements in clinical trials and financial stability.
Read more →NBTX▼ -5.3%on this news
AMF DECLARATION exhibit991may152025 2025DD1038006 FR0011341205 - DD187429 15 mai 2025 INFORMATION D claration individuelle relative aux op rations des personnes mentionn es l'article L.621-18-2 du Code mon taire et finan
The AMF recently received a notification concerning an acquisition made by Bartholomeus van Rhijn of Nanobiotix. The transaction, recorded on May 12, 2025, involved the purchase of 10,000 shares at a unit price of 2.90 Euro on Euronext Paris. This individual declaration pertains to operations involving high-level executives or closely related persons, highlighting potential regulatory implications under the French Monetary and Financial Code. The notification is the initial report and emphasizes that it hasn't undergone AMF scrutiny yet.
Read more →NBTXNanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Nanobiotix is set to participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference on May 20, 2025, at NASDAQ. The event will feature presentations from the company's Chief Financial and Business Officer, Bart van Rhijn. This participation underscores Nanobiotix's commitment to advancing its pioneering nanoparticle-based treatments for cancer and other significant diseases. The conference will be accessible via a live webcast for investors and interested parties.
Read more →NBTX▲ +6%on this news
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Nanobiotix announced positive results from a Phase 1 study of JNJ-1900 (NBTXR3) in patients with locally advanced or borderline resectable pancreatic cancer. The study demonstrated a median overall survival of 23 months and a median local progression-free survival of 13.3 months. Additionally, 59% of patients showed CA19-9 normalization, which is associated with improved survival. Investigators concluded that further evaluation in a randomized study is warranted, and a new cohort combining JNJ-1900 with standard-of-care concurrent chemotherapy is underway.
Read more →NBTX▲ +7.7%on this newsshared move
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Nanobiotix has announced the presentation of full results from a Phase 1 study evaluating JNJ-1900 (NBTXR3) for patients with locally advanced or borderline resectable pancreatic cancer. The results will be presented by Dr. Eugene Koay at the ESTRO 2025 Annual Meeting. Following the presentation, Nanobiotix will host a conference call to discuss the data further. This study represents a step forward in the evaluation of NBTXR3's efficacy and safety in a challenging cancer indication.
Read more →NBTXAMF ATTESTATION exhibit991april142025 2025DD1031953 FR0011341205 - DD187019 14 avril 2025 INFORMATION D claration individuelle relative aux op rations des personnes mentionn es l'article L.621-18-2 du Code mon taire et f
The article discusses recent transactions involving the shares of Nanobiotix (ticker: NBTX) as reported to the French Financial Markets Authority (AMF). It includes details of acquisitions and disposals of shares executed on specific dates in April 2025. The reported transactions were made on Euronext Paris, with varying prices per share. This notification has not undergone AMF oversight and is solely the declarant's responsibility.
Read more →NBTXAMF ATTESTATION exhibit991april102025 2025DD1031083 FR0011341205 - DD186943 09 avril 2025 INFORMATION D claration individuelle relative aux op rations des personnes mentionn es l'article L.621-18-2 du Code mon taire et f
Nanobiotix recently reported a series of transactions involving the acquisition of its shares on Euronext Paris between April 3 and April 8, 2025. The transactions totaled 30,000 shares at varying unit prices, with the last acquisition happening at €2.9939 per share. The activity may reflect strategic moves within the company or confidence from insiders. However, this notification is not subject to AMF control and is based solely on the report from the declarant.
Read more →NBTX▼ -5%on this news
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
NANOBIOTIX (NBTX) reported operational updates and financial results for 2024, highlighting progress in its global development program for JNJ-1900 (NBTXR3), particularly in lung and head and neck cancers. The company is on track with key clinical trials and has extended its cash runway into mid-2026 through disciplined financial strategies. However, they reported a significant negative revenue impact due to a change in sponsorship for the NANORAY-312 study. The launch of the Curadigm platform aims to enhance drug design and development, positioning NANOBIOTIX for future growth.
Read more →NBTXNANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Nanobiotix announced that it will report its financial results for the fourth quarter and full year of 2024 on April 2, 2025. This announcement will be followed by a conference call on April 3, where executives will review year-end results and provide an update on business activities. The company is noted for its innovative nanoparticle-based therapies aiming to enhance cancer treatments. Nanobiotix maintains a strong presence in both Europe and the U.S. with innovative technology platforms.
Read more →NBTXNanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Nanobiotix has announced the first data from the completed dose escalation part of a Phase 1 study for NBTXR3 as a second-line therapy for patients with locally advanced non-small cell lung cancer (NSCLC). The preliminary results indicate a favorable safety profile and promising early efficacy signals, with a 12-month overall survival rate of 83%. The expansion phase of the study is currently ongoing, with initial injections having been completed. These findings suggest NBTXR3 could offer a novel treatment option for patients with limited alternatives after prior therapies have failed.
Read more →NBTXNANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
NANOBIOTIX has announced the presentation of data from two Phase 1 studies concerning JNJ-1900 (NBTXR3) at the upcoming European Lung Cancer Conference. These studies aim to evaluate the safety and efficacy of NBTXR3, particularly in patients with unresectable, locoregional recurrent non-small cell lung cancer (NSCLC). The data will be presented by principal investigators from well-known medical institutions, highlighting the innovative nature and collaborative approach of Nanobiotix in cancer treatment development.
Read more →NBTXNANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Nanobiotix has amended its global licensing agreement with Johnson & Johnson, enhancing its financial position and extending cash visibility to mid-2026. The deal structure now relieves Nanobiotix of certain funding obligations while allowing it to benefit from significant potential milestone payments, adjusted to approximately $2.6 billion. Johnson & Johnson will cover nearly all costs for the ongoing Phase 3 trial of NANORAY-312, which is crucial for the company’s upcoming drug development. The adjustments may position Nanobiotix for sustained growth and reduced operational costs going forward.
Read more →NBTXNanobiotix to Participate in Multiple Investor Conferences in February and March 2025
Nanobiotix, a late-stage biotechnology company focused on innovative cancer treatments, announced its participation in two upcoming investor conferences in February and March 2025. The events will feature key company executives, including the CEO and CFO, who will discuss the company's nanoparticle-based therapeutic approaches. These presentations aim to increase investor awareness and highlight the company's commitment to advancing treatment possibilities for major diseases. The webcasts will be available for viewing post-event on the company's investor relations page.
Read more →NBTX▲ +7.3%on this news
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
NANOBIOTIX has commenced a Phase 2 clinical trial, known as the CONVERGE study, for JNJ-1900 (NBTXR3) in patients with Stage 3 unresectable non-small cell lung cancer. This trial aims to analyze the effectiveness of this novel radioenhancer when used alongside standard chemoradiation treatments. With the first patient dosed, the company hopes to further demonstrate the value of NBTXR3 in cancer therapy, building upon its previous successes in related indications. Overall, this marks a pivotal step in expanding treatment options for lung cancer patients.
Read more →NBTXNANOBIOTIX to Introduce Vision for Transforming Drug Design and Development with Next Nanotherapeutic Platform on 19 December 2024
Nanobiotix has announced its upcoming virtual event scheduled for December 19, 2024, titled 'Accelerating the Future of Nanotherapeutics.' The event will feature company executives discussing the Curadigm Nanoprimer Platform, which aims to improve drug bioavailability while reducing side effects. Despite the optimistic outlook, the article notes that the company's financial future faces uncertainties that could impact its projections.
Read more →NBTXPDMR NOTIFICATIONS PURSUANT TO MAR exhibit991december16 ! #$%&'( '))*%+ ',-.+&/('., 0 1'+%2(.+3) 4')25.)*+%678 9:; = ?@9 : 7?A B88: ;9C8D E9@7 @78 FGHI JKLM LNNOJP LQRSPKTMLSQUVWXYZ[W\]ZYZ _ a b ca ad e fgdg ghh d ia adc
The article contains a notification regarding transactions related to Nanobiotix (NBTX), specifically concerning stock acquisitions by key individuals within the company. The transactions occurred in December 2024 and were registered with regulatory authorities according to relevant financial codes. The document emphasizes that these notifications have not been subject to review by the French financial markets authority (AMF), placing full responsibility on the declarant. Additionally, the article includes details about the transactions such as the price per share and volumes involved.
Read more →NBTXPDMR NOTIFICATIONS PURSUANT TO MAR exhibit991pdmrnotificati ! #$%&'( '))*%+ ',-.+&/('., 0 1'+%2(.+3) 4')25.)*+%678 9:; = ?@9 : 7?A B88: ;9C8D E9@7 @78 FGHI JKLM LNNOJP LQRSPKTMLSQUVWXYZ[W\]ZYZ _ a b ca ad e fgdg ghh d ia
Nanobiotix has issued a notification in compliance with European regulations pertaining to transactions by people in managerial roles. The notification details transactions conducted by Bartholomeus van Rhijn, who has disclosed the acquisition of shares at various price points on December 9, 2024. This action involves a total volume of 30,600 shares, with an average price of €3.0863. The notification emphasizes compliance with personal data regulations and outlines the exclusive responsibility of the declarant.
Read more →NBTXNANOBIOTIX Announces Completion of Phase 1 Study of NBTXR3 (JNJ-1900) in Pancreatic Cancer
NANOBIOTIX has announced the completion of a Phase 1 study of NBTXR3 (JNJ-1900) in patients with locally advanced or borderline resectable pancreatic cancer. The study revealed encouraging overall survival results of 23 months, which is an improvement over historical control outcomes. The FDA has approved an amendment to launch a new cohort evaluating NBTXR3 in combination with standard-of-care chemotherapy, with recruitment currently ongoing. Results from this study phase are scheduled for presentation at a medical congress in the first half of 2025.
Read more →NBTXNANOBIOTIX Provides Third Quarter 2024 Update and Progress on Nanotherapeutics Platforms
NANOBIOTIX provided a third quarter update emphasizing progress on its nanotherapeutics platforms, including the transfer of US sponsorship for the NANORAY-312 study on NBTXR3, indicating steps towards potential regulatory submission. The company welcomed new members to its Supervisory Board to bolster its growth strategy. Financially, NBTX maintains a robust cash position of €53.2 million, projected to support its operations through 2025. Notable updates on clinical studies for pancreatic and lung cancers are anticipated in 2024 and 2025, respectively.
Read more →NBTXNANOBIOTIX to Participate in Multiple Investor Conferences in November
Nanobiotix (NBTX) will take part in several key investor conferences in November 2024, including Guggenheim's Inaugural Healthcare Innovation Conference, the Stifel Healthcare Conference, and the Jefferies London Healthcare Conference. Company leadership, including CEO Laurent Levy and CFO Bart van Rhijn, will present and participate in fireside chats. These engagements aim to discuss their pioneering nanoparticle-based cancer treatments and enhance the company's visibility in the biotechnology space.
Read more →NBTXNANOBIOTIX Provides Business Update and Reports Half Year 2024 Financial Results
NANOBIOTIX has released its half-year financial results for 2024, reporting a revenue increase to €9.3 million, driven by an agreement with Janssen Pharmaceutica. The company anticipates several clinical milestones over the next 12-18 months, which may broaden the patient population for its lead candidate NBTXR3. Despite a net loss of €21.9 million, improvements were noted compared to the previous year. The company's cash and equivalents are sufficient to fund operations into Q4 2025, ensuring continued investment in research and development.
Read more →NBTXNANOBIOTIX Announces Two Key Supervisory Board Additions Intended to Further Equip the Company for Sustainable Long-Term Growth
NANOBIOTIX announced the nomination of Dr. Margaret A. Liu and Ms. Anat Naschitz to its Supervisory Board, aiming to strengthen its long-term growth strategy. Dr. Liu, a specialist in vaccines and immunotherapy, and Ms. Naschitz, a seasoned life sciences investor, bring invaluable experience that aligns with the company's focus on nanotechnology for cancer treatments. Their expertise is expected to enhance Nanobiotix’s oncology initiatives, especially regarding their lead product, NBTXR3. The nominations will be ratified at the upcoming shareholders' meeting.
Read more →NBTX▼ -12.2%on this newsshared move
Nanobiotix to Present at H.C. Wainwright 26th Annual Global Investment Conference
Nanobiotix has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference, scheduled for September 11, 2024, in New York. Company leaders Laurent Levy and Bart Van Rhijn will host a fireside chat that will be webcast live. This event reflects the company's efforts to engage with investors and showcase their innovative therapeutic approaches in oncology. Nanobiotix, based in Paris, is known for its advanced nanotechnology platforms aimed at improving treatment outcomes for cancer patients.
Read more →NBTX▼ -8.1%on this news
NANOBIOTIX to Host Virtual KOL Event Discussing Potential of NBTXR3 Combined With Immunotherapy in Head and Neck Cancer and Beyond on June 18, 2024
Nanobiotix (NBTX) will host a virtual Key Opinion Leader (KOL) event on June 18, 2024, to discuss the potential of NBTXR3 in combination with immunotherapy for treating head and neck cancer. Notable speakers will include coordination investigators from its recent study, which showed encouraging data on disease control and tumor response. The event will also cover the mechanisms of action of NBTXR3 and the challenges faced in treating head and neck cancer. This presentation aims to provide deeper insights into how NBTXR3 can benefit patients resistant to previous treatments.
Read more →NBTXNANOBIOTIX Announces Presentation of new Data From Phase 1 Immunotherapy Program at the 2024 Annual Meeting of the American Society for Clinical Oncology Followed by an Investor Conference Call
Nanobiotix announced the presentation of new data from its Phase 1 immunotherapy program involving NBTXR3 at the ASCO 2024 meeting. The Study 1100 results will showcase early signs of efficacy in patients with recurrent or metastatic head and neck cancer. Following the presentation, the company will hold an investor conference call to discuss the findings and future plans. This event marks a crucial moment for Nanobiotix as it seeks to expand treatment options for cancer patients.
Read more →NBTX▲ +6.3%on this newsshared move
NANOBIOTIX to Present at the Jefferies Global Healthcare Conference
Nanobiotix announced its participation in the Jefferies Global Healthcare Conference, where CFO Bart Van Rhijn will lead a fireside chat. The event is scheduled for June 5, 2024, in New York City, and will focus on the company's advanced, physics-based therapeutic approaches in oncology. This conference presents an opportunity for Nanobiotix to showcase its innovations and engage with potential investors and collaboration partners. The company has a strong patent portfolio and a commitment to enhancing cancer treatment possibilities.
Read more →NBTX▼ -12.5%on this newsshared move
NANOBIOTIX Provides First Quarter 2024 Operational and Financial Update
Nanobiotix, a biotechnology firm focused on cancer treatments, released its operational and financial update for Q1 2024. The company reported cash and cash equivalents of €58.9 million, anticipated to support operations until Q3 2025, aided by a $20 million milestone payment. A conference call is scheduled to discuss business activities and answer questions from participants. Despite the positive financial outlook, the company acknowledged certain risks related to its cash runway forecasts.
Read more →NBTXNanobiotix Announces Progress in Global NBTXR3 Development Collaboration Highlighting Robust Pipeline and Pathway to Long-Term Growth
Nanobiotix has announced strategic updates for the global NBTXR3 development collaboration, aimed at long-term growth. Significant progress includes the transfer of the Phase 3 trial sponsorship in head and neck cancer and the receipt of FDA approval for a new Phase 2 study in stage 3 lung cancer. The company is modifying the head and neck cancer study to enhance regulatory pathways, while also preparing for potential regulatory submissions based on expected positive trial results. This collaboration with Janssen Pharmaceutica is expected to bolster Nanobiotix's capabilities in advancing nanoparticle-based therapies.
Read more →NBTXNANOBIOTIX to Announce First Quarter Operational and Financial Update on May 22, 2024
Nanobiotix is scheduled to announce its financial and operational results for the first quarter of 2024 on May 22, 2024. This will be followed by a conference call and webcast where executives will review the results and discuss business activities. Additionally, the company has announced its next Annual General Meeting to be held on May 28, 2024, providing an opportunity for shareholder engagement. Nanobiotix continues to position itself as a pioneer in physics-based cancer therapies.
Read more →NBTX▲ +6.4%on this newsshared move
NANOBIOTIX Announces US FDA Protocol Acceptance for New Randomized Phase 2 Study Evaluating NBTXR3 for Patients with Stage Three Lung Cancer
Nanobiotix has announced that the U.S. FDA has issued a Study May Proceed Letter for a Phase 2 study evaluating NBTXR3 in patients with stage 3, unresectable non-small cell lung cancer. This acceptance is part of a broader strategy to develop NBTXR3, a nanoparticle-based therapeutic, that aims to induce tumor cell death when activated by radiotherapy. The company views this as a critical step in reaching millions of cancer patients globally. The NBTXR3 collaboration with Janssen Pharmaceutica NV showcases the potential for innovative cancer treatments.
Read more →NBTXNANOBIOTIX Provides Business Update and Reports Full Year 2023 Financial Results
NANOBIOTIX reported a successful year in 2023, highlighted by a global licensing agreement with Janssen with a focus on NBTXR3, a novel radioenhancer for cancer treatment. The company demonstrated prolonged survival results in head and neck cancer and plans to present multiple clinical data points in 2024. Financially, NANOBIOTIX ended the year with €75.3 million in cash, providing the necessary resources to enhance its pipeline. The company also filed its 2023 Universal Registration Document and Annual Report with respective financial authorities.
Read more →NBTXNANOBIOTIX to Announce Fourth Quarter and Full Year 2023 Operational and Financial Update on April 24, 2024
Nanobiotix, a biotechnology company focused on innovative cancer treatments, has announced that it will report its financial and operational results for Q4 2023 and the full year on April 24, 2024. Following the results release, a conference call will be held on April 25 to discuss the findings and answer participant questions. The company is based in Paris and has a prominent presence in nanotechnology applied to oncology and other health disorders.
Read more →NBTXNanobiotix Announces Completion of Phase 1 Dose Escalation and NBTXR3 Recommended Phase 2 Dose for the Treatment of Inoperable, Recurrent Lung Cancer in Patients Amenable to Re-Irradiation
Nanobiotix has successfully completed the Phase 1 dose escalation part of its study for NBTXR3, a radioenhancer designed for inoperable, recurrent non-small cell lung cancer (NSCLC) patients. The recommended Phase 2 dose has been established, supporting further clinical development. The study has demonstrated injection feasibility and a favorable safety profile, allowing for ongoing evaluations of safety and early efficacy signals as the trial progresses. The company's collaboration with The University of Texas MD Anderson Cancer Center highlights its commitment to advancing treatment options for this challenging patient population.
Read more →NBTXNanobiotix to Present at Upcoming Investor Conferences in March
Nanobiotix, a late-stage clinical biotechnology company, announced its participation in two upcoming investor conferences. The Guggenheim Healthy Altitudes Summit and the Leerink Partners Global Biopharma Conference will feature presentations by key executives, aimed at expanding treatment possibilities for cancer patients. The events will include live webcasts to enhance investor engagement. This initiative reflects the company’s commitment to transparency and outreach within the biopharma community.
Read more →NBTXNanobiotix to Present at the Guggenheim 6th Annual Biotechnology Conference
Nanobiotix announced that executives Laurent Levy and Bart Van Rhijn will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on February 7, 2024. The event will be available via live webcast, enhancing the company's outreach and engagement with investors. Nanobiotix focuses on innovative physics-based approaches to improve cancer treatment outcomes.
Read more →NBTXNanobiotix Announces Achievement of $20M Development Milestone Payment Related to Ongoing Global Phase 3 Head and Neck Cancer Study
Nanobiotix has announced the achievement of a $20 million milestone payment from Janssen Pharmaceutica following the operational requirements of its global Phase 3 study for NBTXR3, a new treatment for head and neck cancer. This represents a significant step in their collaboration and aims to bring this potentially first-in-class therapy to market. NBTXR3 operates by utilizing hafnium oxide nanoparticles activated via radiotherapy to enhance tumor cell destruction, thereby promoting an adaptive immune response. The company has plans for further evaluation across various solid tumors with potential for broad applications in oncology.
Read more →NBTXNanobiotix Partner LianBio Assigns Its Development and Commercialization Rights for NBTXR3 in China and Other Asian Markets
Nanobiotix has announced that its partner, LianBio, has assigned its development and commercialization rights for the cancer treatment NBTXR3 to Janssen Pharmaceutica in several Asian countries. This agreement streamlines the development and commercialization process and secures economic terms for Nanobiotix, including up to $220 million in potential milestone payments. NBTXR3 is a novel oncology product designed for intratumoral injection, which is activated by radiotherapy, and has shown promising results in clinical settings. The deal reflects ongoing efforts to expand NBTXR3’s reach, especially in light of its potential to treat various solid tumors effectively.
Read more →NBTXNanobiotix Announces Closing of the Remaining $4.8 Million Investment From Johnson & Johnson Innovation – JJDC, Inc.
Nanobiotix has successfully completed a $4.8 million investment from Johnson & Johnson Innovation, which will aid in extending its operational runway until mid-2025. The funding comes through a subscription of additional ordinary shares and is contingent upon regulatory approvals. This initiative reflects continued confidence in Nanobiotix's potential in the biotechnology sector, particularly relating to its innovative cancer treatments. However, it also results in a slight dilution of existing shares, which may impact current shareholders.
Read more →NBTXNANOBIOTIX Provides Third Quarter 2023 Operational and Financial Update
Nanobiotix has provided a positive operational and financial update for Q3 2023, highlighting a significant global licensing agreement with Janssen for its investigational drug NBTXR3. Clinical data from various studies have demonstrated promising survival rates and local control in cancers, including head and neck and pancreatic cancer. The company successfully raised €50.9 million, extending its financial runway, and has multiple upcoming clinical readouts planned over the next 18 months. Additionally, the removal of an EIB cash covenant has further strengthened its financial position.
Read more →NBTXNANOBIOTIX to Announce Third Quarter 2023 Operational and Financial Update on November 13, 2023
NANOBIOTIX announced it will release its financial results for the third quarter ending September 30, 2023, on November 13, 2023. The announcement will be followed by a conference call on November 14, where company executives will review operational progress and discuss business activities. Participants can access the call through various live dial-in options, and a webcast will be available for broader accessibility. NANOBIOTIX focuses on innovative physics-based therapies aimed at improving cancer treatment outcomes.
Read more →NBTXNANOBIOTIX Announces the Availability of a Prospectus in Connection with Capital Increases Raising Total Gross Proceeds of Approximately $50M and the Exercise by the Underwriters of the Over-Allotment Option for an Additional Amount of Approximately $3.6M
Nanobiotix has announced the availability of a prospectus approved by the French Financial Markets Authority for two share capital increases yielding roughly $50 million in gross proceeds. The first capital increase attracted qualified investors with approximately $30 million, complemented by an additional $3.6 million from underwriter over-allotments. Johnson & Johnson Innovation is notably contributing $20.2 million to the second capital increase, with potential further investment pending regulatory approval. This financing is expected to enhance Nanobiotix's capacity for ongoing clinical development and operations.
Read more →NBTX▼ -14%on this newsshared move
NANOBIOTIX Announces Pricing of a Capital Increase Raising Total Gross Proceeds of $55M
Nanobiotix has successfully priced a global capital increase through a follow-on offering, raising total gross proceeds of approximately $55 million. The offerings include both American Depositary Shares and Ordinary Shares, primarily aimed at qualified investors in Europe and the U.S. Johnson & Johnson Innovation is set to subscribe up to $25 million in Ordinary Shares, contingent on regulatory approval. The company plans to use the proceeds to support its NANORAY-312 Phase 3 clinical trial and enhance production capacity for NBTXR3, along with supporting other R&D efforts.
Read more →NBTX▼ -8%on this news· ran to -21% by day 1shared move
NANOBIOTIX Announces Launch of Global Follow-On Offering and a Concurrent Private Placement Along with the Removal of the EIB Cash Covenant
NANOBIOTIX has announced the launch of a $30 million global follow-on offering, alongside a concurrent private placement of $25 million by Johnson & Johnson Innovation. The company plans to use the proceeds to advance its Phase 3 clinical trial for head and neck cancers, among other initiatives. The offering is subject to market conditions and regulatory approvals, with final amounts to be determined through a book-building process. Trading of its shares will temporarily stop as part of this capital increase strategy.
Read more →NBTXNANOBIOTIX Announces Updated Preliminary Results From Phase 1 Pancreatic Cancer Trial and New Exploratory Analysis From Completed Phase 1 Head and Neck Cancer Trial at ESMO 2023
Nanobiotix has announced updated preliminary results from its Phase 1 trials for NBTXR3 in locally advanced pancreatic cancer (LAPC) and head and neck cancer, which were presented at ESMO 2023. The studies demonstrated a favorable safety profile and promising efficacy, with median overall survival in LAPC patients reaching 23 months, compared to historical rates of 19.2 months. Notably, NBTXR3 showed strong objective response rates that correlated with extended survival in elderly and frail head and neck cancer patients. These findings support future clinical development, including an ongoing global Phase 3 study.
Read more →NBTXNanobiotix Announces the Presentation of the Final Efficacy Analysis From Phase 1 Cohort Expansion Evaluating NBTXR3 in Locally Advanced Head and Neck Cancer Showing Median Progression-Free Survival of 16.9 Months and Median Overall Survival of 23.1 Months
Nanobiotix announced the final results of Study 102, demonstrating significant improvements in survival outcomes for patients with locally advanced head and neck cancer treated with the radioenhancer NBTXR3. The median progression-free survival was reported at 16.9 months, and median overall survival reached 23.1 months, both of which exceed historical benchmarks. The findings suggest that NBTXR3 presents a promising therapeutic option for elderly patients who are often unable to tolerate standard treatments, with a conference call scheduled for further discussion on October 5, 2023.
Read more →NBTX▲ +5%on this newsshared move
NANOBIOTIX Announces Oral Presentation of Final Results From a Phase 1 Dose Expansion Study Evaluating NBTXR3 in Head and Neck Cancer at the 65th Annual Meeting of the American Society for Radiation Oncology
NANOBIOTIX has announced the oral presentation of final results from a Phase 1 dose expansion study evaluating NBTXR3, a radioenhancer for head and neck cancer, at the 65th Annual Meeting of ASTRO. The presentation will occur on October 4, 2023, and will include key findings related to elderly patients with locally advanced conditions. The data has garnered attention, being included in two scientific highlight sessions for discussion. Following the presentation, the CEO will discuss the results in a conference call on October 5, 2023.
Read more →NBTXNANOBIOTIX Announces Presentation of First Data From Phase 1 Study Evaluating NBTXR3 for Patients With Locally Advanced Pancreatic Cancer
NANOBIOTIX announced preliminary findings from a Phase 1 study evaluating NBTXR3 for patients with locally advanced pancreatic cancer. The data, presented at the AACR 2023 Special Conference, indicated a local disease control rate of 92.3% in evaluable patients and a median overall survival of 21 months. The study demonstrated feasibility of the treatment with a tolerable safety profile. These results support the further development of NBTXR3 in pancreatic cancer and highlight the urgent need for effective treatment options in this patient population.
Read more →NBTXNANOBIOTIX Provides Business Update and Financial Results for the First Half of 2023
Nanobiotix has made significant strides in its business operations, highlighted by a partnership with Janssen Pharmaceutica NV to commercialize its novel radioenhancer NBTXR3. The company reported an increase in cash reserves thanks to upfront payments from the agreement and announced the appointment of a new chief medical officer to enhance its oncology capabilities. With key Phase 1 clinical data expected imminently and a robust pipeline of ongoing trials, Nanobiotix is optimistic about its future prospects, though it continues to navigate challenges with rising R&D costs and a reported net loss.
Read more →NBTXto the Company's Report on Form 6-K furnished to the SEC on
The Company entered a licensing agreement with Janssen Pharmaceutica NV for NBTXR3, granting Janssen exclusive rights to develop and commercialize the product worldwide, excluding markets where it has existing commitments. A joint strategy committee will oversee the collaboration between the two entities, ensuring alignment on development strategies. The Company retains certain rights to conduct ongoing studies and maintain its INDs, while Janssen will handle regulatory and manufacturing responsibilities within the licensed territories.
Read more →NBTX▼ -10.8%on this news
Nanobiotix to Announce Half Year 2023 Financial Results on September 26, 2023
Nanobiotix, a late-stage biotechnology company, has announced that it will release its financial results for the half-year ending June 30, 2023, on September 26, 2023. Following this, a conference call will take place on September 27, 2023, where the CEO and CFO will discuss the results and provide business updates. This announcement highlights the company's ongoing commitment to cancer treatment innovation and investor communication.
Read more →NBTXNANOBIOTIX Strengthens Global Development Capabilities With the Appointment of Veteran Industry Leader Dr. Louis Kayitalire as Chief Medical Officer
NANOBIOTIX has announced the appointment of Dr. Louis Kayitalire as the new Chief Medical Officer. Dr. Kayitalire brings nearly 25 years of experience in biopharmaceuticals, particularly in oncology, and is expected to lead the development of NBTXR3, a novel cancer treatment. This appointment comes as the company focuses on advancing its product, which has shown promise in clinical trials. NBTXR3 is being evaluated for various solid tumors, leveraging its innovative mechanism activated by radiotherapy.
Read more →NBTXNANOBIOTIX to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Nanobiotix, a biotechnology company focused on innovative cancer treatments, will present at the H.C. Wainwright 25th Annual Global Investment Conference on September 11, 2023. CEO Laurent Levy and CFO Bart Van Rhijn will engage in a virtual fireside chat that will be webcasted live. The company has made significant advancements with its lead product candidate, NBTXR3, which is already CE marked for treating soft tissue sarcoma. Established in 2003, Nanobiotix operates from Paris and has a strong patent portfolio in nanotechnology applications for oncology and other fields.
Read more →NBTX▼ -6.1%on this news
NANOBIOTIX Announces Expiration of HSR Waiting Period Regarding the Agreement for Worldwide Co-Development and Commercialization of Potential First-in-Class Radioenhancer NBTXR3
Nanobiotix has announced the expiration of the Hart-Scott-Rodino waiting period for its co-development agreement with Janssen Pharmaceutica NV regarding the potential first-in-class radioenhancer NBTXR3. With this expiration, the agreement becomes effective, enabling Nanobiotix to receive a $30 million upfront cash licensing fee. The company, known for its innovative approaches in cancer treatment, aims to leverage this agreement for further development and commercialization of NBTXR3, already authorized in Europe for treating soft tissue sarcoma.
Read more →NBTXNANOBIOTIX to Host Extraordinary General Meeting of Shareholders on September 1st, 2023
Nanobiotix will hold an Extraordinary General Meeting of Shareholders on September 1st, 2023, to seek approval for the issuance of up to 959,638 shares to Johnson & Johnson Innovation – JJDC, Inc. This initial capital increase amounts to $5 million, contributing to the company's growth strategy. The meeting will also outline the terms of participation and voting instructions for shareholders. Nanobiotix is recognized for its innovative therapeutic approaches in oncology, primarily focusing on its lead product candidate, NBTXR3.
Read more →NBTXNANOBIOTIX Announces First Patient Injected in New Phase 1/2 Study Evaluating Radiotherapy-Activated NBTXR3 Plus Anti-PD-1 for Patients With Advanced Cancers
Nanobiotix has initiated a Phase 1/2 clinical study evaluating its NBTXR3 treatment combined with anti-PD-1/L-1 immune checkpoint inhibitors in patients with advanced cancers. The study investigates the potential of NBTXR3 activated by radiotherapy to improve outcomes for solid tumor malignancies, particularly those that have metastasized to the lungs or liver. This marks a significant expansion of Nanobiotix's partnership with The University of Texas MD Anderson Cancer Center, which now includes five actively recruiting trials. Promising early results from previous studies suggest the efficacy and safety of NBTXR3, positioning it as a potentially scalable and transformative oncology product.
Read more →NBTX▲ +24.5%on this news
NANOBIOTIX Announces License Agreement for Worldwide Co-development and Commercialization of Potential First-In-Class Radioenhancer NBTXR3
Nanobiotix has entered a global licensing and co-development agreement with Janssen Pharmaceutica NV for its investigational radioenhancer NBTXR3, aiming to expand its application in oncology. As part of the deal, Nanobiotix will receive up to $60 million in cash and operational support, alongside eligibility for substantial success-based payments totaling up to $1.8 billion. The agreement is expected to accelerate the clinical development of NBTXR3, which is currently under evaluation in multiple studies for solid tumors, including a pivotal Phase 3 trial for head and neck cancer. This collaboration signifies a strategic partnership that could enhance treatment options for patients with various cancer types.
Read more →NBTX▼ -7.2%on this news
NANOBIOTIX Provides First Quarter 2023 Operational and Financial Update
NANOBIOTIX has released its operational and financial update for Q1 2023, emphasizing significant progress in its clinical trials, specifically for its radioenhancer NBTXR3 in head and neck cancer. The company is focusing on upcoming milestones, including final data from Study 102 and developments in pancreatic cancer collaboration. A new Chief Medical Officer is expected to join the team in Q3 2023 to bolster their clinical strategies. However, the company faces challenges in securing necessary capital and ensuring successful outcomes from its ongoing studies.
Read more →NBTX▲ +229%on this news
NANOBIOTIX Entering Final Contract Negotiations Following Agreement to Non-Binding Term Sheet for Development and Commercialization of NBTXR3 With a Major Global Pharmaceutical Company
NANOBIOTIX is entering final contract negotiations following a non-binding agreement for the development and commercialization of NBTXR3 with a major pharmaceutical company. The lead candidate is being explored for its efficacy in oncology, particularly for treating head and neck squamous cell carcinoma. While there are positive indications from ongoing clinical studies, the completion of the deal hinges on further negotiations and corporate approvals.
Read more →NBTX▲ +14.4%on this news· ran to -41% by day 3
NANOBIOTIX Provides Business Update and Reports Full Year 2022 Financial Results
Nanobiotix has provided a business update alongside its financial results for 2022, highlighting continued progress in its lead candidate NBTXR3, particularly through the pivotal Phase 3 trial NANORAY-312 which continues across 104 sites in 25 countries. The company has bolstered its leadership with the anticipated addition of a new Chief Medical Officer and has made notable advances in clinical studies. While revenue generation remains absent and net losses have increased, the company holds a cash reserve of €41.4 million as of year-end 2022, indicating a strategic focus on its drug development trajectory.
Read more →NBTX▼ -5.3%on this news· ran to -36% by day 3shared move
NANOBIOTIX to Provide Operational Update and Report Full Year 2022 Financial Results on April 24, 2023
Nanobiotix will release its financial results for the full year ending December 31, 2022, on April 24, 2023, after US market close. A subsequent conference call and live audio webcast are scheduled for April 25, 2023, where company executives will review the year-end results and update on business activities. The firm is noted for its innovative approaches in cancer treatment, particularly through its proprietary product NBTXR3, which has received market authorization in Europe.
Read more →NBTXNanobiotix to Postpone Full Year 2022 Financial Results and Conference Call
Nanobiotix announced the postponement of its full year 2022 financial results, originally set for March 28, 2023. The company seeks additional time to complete year-end closing procedures. The new schedule for these results and the accompanying conference call will be communicated in a future press release.
Read more →NBTX▲ +8.9%on this news
Nanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023
Nanobiotix will provide an operational update and financial results for the year ending December 31, 2022, on March 28, 2023. A conference call will follow on March 29, where the CEO and CFO will discuss year-end results and company activities. The company focuses on its lead product candidate, NBTXR3, aimed at treating cancer with promising safety and efficacy data. Ongoing developments include collaborations with leading cancer centers and exploration of NBTXR3 for various tumor types.
Read more →NBTX▼ -5.7%on this news
NANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck Cancer
Patients randomized in all planned major regions for pivotal phase 3 NANORAY-312 study with the United States added to Europe and Asia NANORAY-312 now has sites activated across 80 sites globally Phase 3 futility analysis expected in 2H 2023, with interim Phase 3 data expected
Read more →NBTX▼ -5.7%on this newsshared move
NANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract Statement
PARIS and CAMBRIDGE, Mass., Dec. 21, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announce
Read more →NBTXNANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx Conference
PARIS and CAMBRIDGE, Mass., Nov. 15, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced
Read more →NBTX▲ +7.9%on this newsshared move
NANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic Cancer
Data show that radiotherapy-activated NBTXR3 was feasible and well tolerated in the complete dose escalation part of a Study 2019-1001, a phase 1 evaluation of NBTXR3 for patients with locally advanced pancreatic adenocarcinoma The recommended phase 2 dose for radiotherapy-activ
Read more →NBTX▲ +7.9%on this newsshared move
NANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of Cancer
Data show that radiotherapy-activated NBTXR3 followed by anti-PD-1 was feasible and well tolerated in the complete dose escalation part of the Company’s phase 1 immunotherapy study with a recommended phase 2 dose established at 33% of gross tumor volume in all 3 cohorts Results
Read more →NBTX▲ +7.9%on this newsshared move
NANOBIOTIX Provides Third Quarter 2022 Operational and Financial Update
Established recommended Phase 2 dose (RP2D) for NBTXR3 plus anti-PD-1 in patients with locoregional recurrent and recurrent and/or metastatic head and neck cancer, lung metastases from any primary tumor, or liver metastases from any primary tumor Updated Phase 1 NBTXR3 plus anti
Read more →NBTXNANOBIOTIX Voting Rights and Shares Capital of the Company
In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorité des Marchés Financiers) PARIS, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Market: Euronext Paris / Nasdaq Euronext Compartment:
Read more →NBTXNANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3
PARIS and CAMBRIDGE, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO – NASDAQ: NBTX – the “Company”), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced th
Read more →NBTX▼ -7.6%on this newsshared move
NANOBIOTIX to Present at the Jefferies London Healthcare Conference
PARIS and Cambridge, Mass., Oct. 31, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext : NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announce
Read more →NBTXNANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022
PARIS and CAMBRIDGE, Mass., Oct. 27, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced
Read more →NBTXNANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment Bank
PARIS and CAMBRIDGE, Mass., Oct. 18, 2022 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO –– NASDAQ: NBTX – the ‘‘Company’’), a late-clinical stage biotechnology company pioneering physics-based approaches to expand treatment possibilities for patients with cancer, today announced
Read more →NBTXNanobiotix: Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit des
Nanobiotix: Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit des March s PARIS--(BUSINESS WIRE)--October 10, 2022--Regulat
Read more →NBTX▼ -6.4%on this news
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022 Pivotal Phase 3 study, NANORAY-312, actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across ~50 sites as
Nanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022 Pivotal Phase 3 study, NANORAY-312, actively enrolling elderly, LA-HNSCC patients ineligible for cisplatin across ~50 sites as LianBio enrolls first patient and continues to ramp up site
Read more →NBTX▼ -9.1%on this news· ran to -20% by day 3shared move
Nanobiotix to Announce Half Year 2022 Financial Results on
Nanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022 Conference Call and Webcast to be Held at 8:00 AM ET / 2:00 PM CET on September 29, 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 22, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO --
Read more →NBTX▼ -8%on this news· ran to -22% by day 3shared move
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy Recommended phase 2 dose establ
Nanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior Immunotherapy Recommended phase 2 dose established at 33% of gross tumor volume in all three cohorts fro
Read more →NBTXNanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024 Debt restructuring supports corporate priorities by realigning deb
Nanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024 Debt restructuring supports corporate priorities by realigning debt obligations with expected development and commercializati
Read more →NBTX▲ +10%on this newsshared move
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer Regional activation for Nanobiotix pivotal Phase 3 trial in head and
NANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck Cancer Regional activation for Nanobiotix pivotal Phase 3 trial in head and neck cancer proceeds as planned with first patient enrolle
Read more →NBTX▲ +10%on this newsshared move
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX Co-Founder and CEO Laurent Levy Named to 2022 PharmaVoice 100 List of Most Inspiring People in Life Sciences PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--September 6, 2022--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company'') (Paris:NANO) (NASD
Read more →NBTXNanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
Nanobiotix to Present During the H.C. Wainwright Global Investment Conference in September 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--August 31, 2022--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company'') (Paris:NANO) (NASDAQ:NBTX), a late-clinical
Read more →NBTX▼ -5.7%on this news
NANOBIOTIX: Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit des
NANOBIOTIX: Voting Rights and Shares Capital of the Company In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulation of the French Financial Markets Authority (Autorit des PARIS--(BUSINESS WIRE)--August 9, 2022--Regulatory News:
Read more →NBTX▼ -11%on this news
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
Half-year Report on the Nanobiotix Liquidity Contract With Gilbert Dupont PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--July 13, 2022--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company"), a late-clinical stage biotechnology company pioneering physics-based
Read more →NBTX▼ -5.6%on this news· ran to -22% by day 3
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company's Share Capital In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit des Ma
NANOBIOTIX: Statement of Total Voting Rights and Shares Forming the Company's Share Capital In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit des March s Financiers (French Financial Markets PARIS--(BUSINES
Read more →NBTX▼ -8.1%on this newsshared move
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications Data reported at the 2022 Annual Meeting of
NANOBIOTIX: New Data Featuring NBTXR3 Plus Chemoradiation and in the Preoperative Setting Support Broad Applicability for Head and Neck Cancer and Other Solid Tumor Indications Data reported at the 2022 Annual Meeting of the American Society for Clinical Oncology NBTXR3 is bein
Read more →NBTX▼ -8.1%on this newsshared move
NANOBIOTIX Annual Shareholders' General Meeting to Be Held on
NANOBIOTIX Annual Shareholders' General Meeting to Be Held on June 23, 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 2, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-stage clinical biotechnology company pioneering physics-based
Read more →NBTXNANOBIOTIX Provides First Quarter Operational and Financial Update On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and nec
NANOBIOTIX Provides First Quarter Operational and Financial Update On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received p
Read more →NBTXNANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX to Present During the Jefferies Healthcare Conference in June 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 17, 2022--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneering physics-b
Read more →NBTX▲ +7.7%on this news
NANOBIOTIX to Participate in Two Upcoming Investor Conferences PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX to Participate in Two Upcoming Investor Conferences PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 11, 2022--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the "Company"), a clinical-stage biotechnology company pioneering physics-based approaches to e
Read more →NBTX▼ -15.3%on this newsshared move
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit des Ma
Nanobiotix: Statement of Total Voting Rights and Shares Forming the Company's Share Capital In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit des March s Financiers (French Financial Markets PARIS--(BUSINES
Read more →NBTX▼ -7.3%on this news· ran to -27% by day 3shared move
NANOBIOTIX to Announce First Quarter 2022 Financial Results on
NANOBIOTIX to Announce First Quarter 2022 Financial Results on May 18, 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 4, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-stage clinical biotechnology company pioneering physics-based
Read more →NBTX▲ +8.6%on this newsshared move
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
New Data Featuring NANOBIOTIX Lead Product Candidate NBTXR3 to Be Presented at the 2022 ASCO Annual Meeting PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the "Company"), a late-stage clinical biotechnology c
Read more →NBTXNANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3 Data presented at the 2022 Annual Mee
NANOBOTIX: New Preclinical Immunotherapy Data Show Boosted Anti-Tumor Immune Activation via Triple Blockade of PD-1, LAG-3, and TIGIT When Combined With Radiotherapy-Activated NBTXR3 Data presented at the 2022 Annual Meeting of the American Association of Cancer Research New da
Read more →NBTXNANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX Announces Filing of the 2021 Universal Registration Document and the 2021 Annual Report on Form 20-F PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 8, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-stage clinical biotechno
Read more →NBTXNANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall
NANOBIOTIX Provides Business Update and Reports Full Year 2021 Financial Results New data from Expansion Study 102 in high-risk, LA-HNSCC patients highlights potential clinical benefit of NBTXR3 showing a median Overall Survival reaching 23 months in evaluable patients; Data wit
Read more →NBTX▲ +8.4%on this news
NANOBIOTIX to Announce Full Year 2021 Financial Results on
NANOBIOTIX to Announce Full Year 2021 Financial Results on March 30, 2022 Conference Call and Webcast to be Held at 8:00 A.M. EDT/2:00 P.M CET on March 31, 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 16, 2022--NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company'')
Read more →NBTXNanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer Data published in Clinical and Translational Radiation Oncology Peer-reviewed cl
Nanobiotix Announces Publication of New Clinical Case Study Highlighting First Patient Experience of NBTXR3 Treatment for Pancreatic Cancer Data published in Clinical and Translational Radiation Oncology Peer-reviewed clinical case study reported preliminary data on the first-i
Read more →NBTXOPERATING AND FINANCIAL REVIEW AND PROSPECTS Unless otherwise indicated or the context otherwise requires, references in this Operating and Financial Review and Prospects to "Nanobiotix," or the "Company" refer to Nanobi
OPERATING AND FINANCIAL REVIEW AND PROSPECTS Unless otherwise indicated or the context otherwise requires, references in this Operating and Financial Review and Prospects to "Nanobiotix," or the "Company" refer to Nanobiotix S.A. and its consolidated subsidiaries. All reference
Read more →NBTXNANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 Data published in the International Journal of Nanobiotechnology Peer-r
NANOBIOTIX Announces Publication of New Preclinical Immunotherapy Data Showcasing the Combination Potential of NBTXR3 With anti-PD-1 and anti-CTLA-4 Data published in the International Journal of Nanobiotechnology Peer-reviewed preclinical data in an anti-PD-1 resistant lung ca
Read more →NBTXNANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in
NANOBIOTIX Provides Corporate Update and Highlights Key 2022 Milestone Targets Evaluation of NBTXR3 for global registration in priority head and neck cancer pathway proceeds with the first European patient randomized in global phase III NANORAY-312 study; US and Asia site activa
Read more →NBTXNANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer First patient randomized in pivotal phase III study evaluating radiotherapy-activated NBT
NANOBIOTIX Announces First Patient Enrolled in NANORAY-312 Global Phase III Registrational Study of NBTXR3 in Head and Neck Cancer First patient randomized in pivotal phase III study evaluating radiotherapy-activated NBTXR3 with or without cetuximab in high-risk elderly patients
Read more →NBTX▼ -7.2%on this newsshared move
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
Nanobiotix Announces Participation at Three Virtual Investor Conferences in January 2022 PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--January 4, 2022--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneeri
Read more →NBTXNANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX to Present at the 4th Annual Evercore ISI HealthCONx Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 17, 2021--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company'') (Paris:NANO) (NASDAQ:NBTX), a late-clinical stage biotechnology c
Read more →NBTX▼ -5.8%on this news
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination Data to be presented at the 36 th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) Dat
NANOBIOTIX Announces New Preclinical Data Highlighting NBTXR3 Immune Priming and Checkpoint Inhibitor Combination Data to be presented at the 36th Annual Meeting of the Society for the Immunotherapy of Cancer (SITC) Data show radiotherapy-activated NBTXR3 increased CD8+ T cell
Read more →NBTXNANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX to Participate in a Fireside Chat at the Jefferies London Healthcare Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--November 3, 2021--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pione
Read more →NBTXNANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy Data presented by Professo
NANOBIOTIX Announces 18.1 Month Median Overall Survival for 41 Evaluable Elderly and Frail Patients With HNSCC in Phase I Expansion Evaluating Nbtxr3 as a Single Agent Activated by Radiotherapy Data presented by Professor Christophe Le Tourneau at the 2021 Annual Meeting of the
Read more →NBTXNANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology Poster presentation by Pr. Christoph
NANOBIOTIX to Present First Survival Data From Priority Head and Neck Cancer Program Among Five Presentations at the 2021 Annual Meeting of the American Society for Radiation Oncology Poster presentation by Pr. Christophe Le Tourneau featuring first OS and PFS data from phase I
Read more →NBTX▼ -5.2%on this news
NANOBIOTIX Provides Third Quarter Operational and Financial Update Published preclinical data in Red Journal supporting the hypothesis that NBTXR3 activated by radiotherapy in combination with anti-PD-1 could effectively
NANOBIOTIX Provides Third Quarter Operational and Financial Update Published preclinical data in Red Journal supporting the hypothesis that NBTXR3 activated by radiotherapy in combination with anti-PD-1 could effectively control primary and metastatic tumors, evoke abscopal effe
Read more →NBTXNANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May "Reprogram" the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect Data Published in the No
NANOBIOTIX Announces Red Journal Publication of Preclinical Data Showing Radioenhancer NBTXR3 May "Reprogram" the Tumor Microenvironment to Overcome Anti-PD-1 Resistance and Evoke Abscopal Effect Data Published in the November 2021 Edition of the International Journal of Radiati
Read more →NBTX▲ +6.5%on this news
STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL AS OF AUGUST 31, 2021 In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulatio
STATEMENT OF TOTAL VOTING RIGHTS AND SHARES FORMING THE COMPANY'S SHARE CAPITAL AS OF AUGUST 31, 2021 In accordance with Articles L.233-8 II of the French Commercial Code and 223-16 of the General Regulations of the Autorit des March s Financiers (French Financial Markets Paris
Read more →NBTXNANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FIRST HALF OF 2021 Positive data from Study 102 Expansion reported in H1 2021 included an overall objective response rate of 82.5% and a complete
NANOBIOTIX PROVIDES BUSINESS UPDATE AND REPORTS FINANCIAL RESULTS FOR THE FIRST HALF OF 2021 Paris, France; Cambridge, Massachusetts (USA); September 8, 2021 - NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneering phy
Read more →NBTX▼ -5.3%on this newsshared move
NANOBIOTIX TO PRESENT AT THE H.C. WAINWRIGHT 23 rd ANNUAL GLOBAL INVESTMENT CONFERENCE Paris, France; Cambridge, Massachusetts (USA)
NANOBIOTIX TO PRESENT AT THE H.C. WAINWRIGHT 23rd ANNUAL GLOBAL INVESTMENT CONFERENCE Paris, France; Cambridge, Massachusetts (USA); September 7, 2021 - NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneering physics-bas
Read more →NBTXNANOBIOTIX PROVIDES SECOND QUARTER OPERATIONAL AND FINANCIAL UPDATE Presented updated results from priority pathways in head and neck cancer and immunotherapy for potential first-in-class radioenhancer NBTX
NANOBIOTIX PROVIDES SECOND QUARTER OPERATIONAL AND FINANCIAL UPDATE Paris, France; Cambridge, Massachusetts (USA); July 20, 2021 - NANOBIOTIX (Euronext: NANO -- NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneering physics-based approaches to ex
Read more →NBTXNANOBIOTIX TO HOST VIRTUAL KOL EVENT DISCUSSING POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN IMMUNOTHERAPY ON JUNE 11, 2021 Paris, France; Cambridge, Massachusetts (USA)
NANOBIOTIX TO HOST VIRTUAL KOL EVENT DISCUSSING POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN IMMUNOTHERAPY ON JUNE 11, 2021 Paris, France; Cambridge, Massachusetts (USA); June 7, 2021 - NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the "Company''), a late-clinical stage biot
Read more →NBTXNANOBIOTIX REPORTS NEW DATA FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN COMBINATION WITH ANTI-PD-1 SHOWING LOCAL OR DISTANT TUMOR REGRESSION IN 76.9% OF EVALUABLE PATIENTS REGARDLESS OF PRIOR ANTI-
NANOBIOTIX REPORTS NEW DATA FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 IN COMBINATION WITH ANTI-PD-1 SHOWING LOCAL OR DISTANT TUMOR REGRESSION IN 76.9% OF EVALUABLE PATIENTS REGARDLESS OF PRIOR ANTI-PD-1 EXPOSURE Data to be Presented at the 2021 Annual Meeting of the Ame
Read more →NBTXNANOBIOTIX ANNOUNCES THE APPOINTMENT OF BART VAN RHIJN AS CHIEF FINANCIAL OFFICER AND MEMBER OF THE EXECUTIVE BOARD TO SUPPORT GLOBAL EXPANSION Paris, France; Cambridge, Massachusetts (USA)
NANOBIOTIX ANNOUNCES THE APPOINTMENT OF BART VAN RHIJN AS CHIEF FINANCIAL OFFICER AND MEMBER OF THE EXECUTIVE BOARD TO SUPPORT GLOBAL EXPANSION Paris, France; Cambridge, Massachusetts (USA); June 1, 2021 - NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company''), a late-cli
Read more →NBTXNANOBIOTIX TO PARTICIPATE IN FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE Paris, France; Cambridge, Massachusetts (USA)
NANOBIOTIX TO PARTICIPATE IN FIRESIDE CHAT AT THE JEFFERIES VIRTUAL HEALTHCARE CONFERENCE Paris, France; Cambridge, Massachusetts (USA); May 26, 2021 - NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneering physics-b
Read more →NBTXNANOBIOTIX ANNOUNCES THE APPOINTMENT OF DR. GARY PHILLIPS AS CHAIRMAN OF THE NANOBIOTIX SUPERVISORY BOARD Paris, France; Cambridge, Massachusetts (USA)
NANOBIOTIX ANNOUNCES THE APPOINTMENT OF DR. GARY PHILLIPS AS CHAIRMAN OF THE NANOBIOTIX SUPERVISORY BOARD Paris, France; Cambridge, Massachusetts (USA); May 25, 2021 - NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pion
Read more →NBTXNANOBIOTIX ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND IMMUNOTHERAPY FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 AT 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLI
NANOBIOTIX ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND IMMUNOTHERAPY FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 AT 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY Paris, France; Cambridge, Massachusetts (USA); May 19, 20
Read more →NBTXCorrection to Release Dated
Correction to Release Dated May 19, 2021 NANOBIOTIX ANNOUNCES UPDATED RESULTS FROM PRIORITY PATHWAYS IN HEAD AND NECK CANCER AND IMMUNOTHERAPY FOR POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 AT 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY Paris, France;
Read more →NBTXNanobiotix to Present at the UBS Global Healthcare Virtual Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
Nanobiotix to Present at the UBS Global Healthcare Virtual Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 12, 2021--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company''), a late-clinical stage biotechnology company pioneering physics-based app
Read more →NBTXNANOBIOTIX PARTNERS WITH LIANBIO TO DEVELOP AND COMMERCIALIZE POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 ACROSS TUMOR TYPES AND THERAPEUTIC COMBINATIONS IN CHINA AND OTHER ASIAN MARKETS LianBio to collab
NANOBIOTIX PARTNERS WITH LIANBIO TO DEVELOP AND COMMERCIALIZE POTENTIAL FIRST-IN-CLASS RADIOENHANCER NBTXR3 ACROSS TUMOR TYPES AND THERAPEUTIC COMBINATIONS IN CHINA AND OTHER ASIAN MARKETS Paris, France; Cambridge, Massachusetts (USA); Shanghai; and Princeton, NJ; May 11, 2021 -
Read more →NBTXNANOBIOTIX ANNOUNCES FIRST QUARTER OPERATIONAL AND FINANCIAL UPDATES Expanded clinical data set supporting tumor agnostic potential of NBTXR3 in presentation of first results in rectal cancer at ASCO-GI 202
NANOBIOTIX ANNOUNCES FIRST QUARTER OPERATIONAL AND FINANCIAL UPDATES Paris, France; Cambridge, Massachusetts (USA); April 29, 2021 - NANOBIOTIX (Euronext : NANO - NASDAQ: NBTX - the Company''), a late-stage clinical biotechnology company pioneering physics-based approaches to e
Read more →NBTXNANOBIOTIX TO PRESENT FOUR POSTERS INCLUDING UPDATES FROM PRIORITY HEAD AND NECK CANCER AND IMMUNOTHERAPY DEVELOPMENT PATHWAYS AT THE 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY New da
NANOBIOTIX TO PRESENT FOUR POSTERS INCLUDING UPDATES FROM PRIORITY HEAD AND NECK CANCER AND IMMUNOTHERAPY DEVELOPMENT PATHWAYS AT THE 2021 ANNUAL MEETING OF THE AMERICAN SOCIETY FOR CLINICAL ONCOLOGY Paris, France ; Cambridge, Massachusetts (USA) ; April 28, 2021 - NANOBIOTIX (E
Read more →NBTXAnnual General Combined Meeting of the Shareholders on April 28th 2021 at 17:00 CET Attendees list 21 Shareholders who gave proxy to the Chairman 2,914,592 Shares representing 3,817,190 Rights 96 Shareholders who voted b
A limited liability company with an executive board and a supervisory board with a share capital of 1,044,776.16 60 RUE DE WATTIGNIES 447 521 600 R.C.S. PARIS Annual General Combined Meeting of the Shareholders Annual General Combined Meeting of the Shareholders on April 28th
Read more →NBTXNANOBIOTIX A limited liability company with an executive board and a supervisory board (soci t anonyme directoire et conseil de surveillance ) Incorporated and organized under the laws of France with a share capital of 1
A limited liability company with an executive board and a supervisory board (soci t anonyme directoire et conseil de surveillance) Incorporated and organized under the laws of France with a share capital of 1,044,776.16 Registered office: 60, rue de Wattignies, 75012 Paris, Fra
Read more →NBTXNANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX Announces Filing of 2020 Universal Registration Document and 2020 Annual Report on Form 20-F PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--April 7, 2021--Regulatory News: NANOBIOTIX (Euronext: NANO - NASDAQ: NBTX - the Company''), a late-stage clinical biotechnology com
Read more →NBTXTime Sensitive Materials Depositary's Notice of Combined General Meeting of Nanobiotix S.A. ADSs: American Depositary Shares. ADS CUSIP No.: 63009J107. ADS Record Date
Depositary's Notice of Combined General Meeting ADSs: American Depositary Shares. ADS CUSIP No.: 63009J107. ADS Record Date: March 26, 2021. Date to determine ADS Holders who are to receive these materials and who are eligible to give voting instructions to the Depositary upon
Read more →NBTXNANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track d
NANOBIOTIX Reports Full Year 2020 Financial Results and Highlights Operational Progress Substantial progress in priority development pathway in head and neck cancer with clinical registration plan announced, Fast Track designation granted by US Food and Drug Administration, and
Read more →NBTXNANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX and PharmaEngine Mutually Agree to Conclude Collaboration PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 4, 2021--Regulatory News: NANOBIOTIX (Euronext : NANO -- NASDAQ: NBTX - the Company''), a clinical-stage biotechnology company pioneering physics-based approach
Read more →NBTXNANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)
NANOBIOTIX to Present at the H.C. Wainwright Global Life Sciences Conference PARIS & CAMBRIDGE, Mass.--(BUSINESS WIRE)--March 3, 2021--Regulatory News: NANOBIOTIX (Paris:NANO) (NASDAQ:NBTX) (Euronext : NANO -- NASDAQ: NBTX - the Company''), a clinical-stage biotechnology compan
Read more →NBTXNANOBIOTIX: Preclinical Data Presented at First AACR Virtual Special Conference on Radiation Science and Medicine Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance, Promotes Strong Abscopal Effect and Long-Term Anti-Can
NANOBIOTIX: Preclinical Data Presented at First AACR Virtual Special Conference on Radiation Science and Medicine Showed NBTXR3 Combo Overcomes Anti-PD-1 Resistance, Promotes Strong Abscopal Effect and Long-Term Anti-Cancer Memory Combo therapy including augmented anti-tumor res
Read more →NBTXNANOBIOTIX 2020 Q4 and Annual Revenues Strong cash position of 119.2M as of
NANOBIOTIX 2020 Q4 and Annual Revenues Strong cash position of 119.2M as of December 31, 2020 Successful completion of U.S. initial public offering and listing on the Nasdaq Global Select Market Publication of promising clinical results and initiation of several clinical studi
Read more →NBTXNANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer First patient injected in phase I trial evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patien
NANOBIOTIX Announces First Patient Injected With NBTXR3 in Esophageal Cancer First patient injected in phase I trial evaluating tumor-agnostic NBTXR3 activated by radiation therapy with concurrent chemotherapy for patients with esophageal cancer This first injection expands eva
Read more →NBTXNanobiotix Subsidiary Curadigm Secures New Collaboration Agreement With Sanofi Focused on Gene Therapy Pipeline Nanobiotix subsidiary, Curadigm, submitted a research project involving its Nanoprimer technology which was
Nanobiotix Subsidiary Curadigm Secures New Collaboration Agreement With Sanofi Focused on Gene Therapy Pipeline Nanobiotix subsidiary, Curadigm, submitted a research project involving its Nanoprimer technology which was selected for the Sanofi iTech Awards Program, as a highly p
Read more →NBTXNanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021 Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) acti
Nanobiotix Announces Positive First Results for Novel NBTXR3 in Rectal Cancer Study at ASCO-GI 2021 Positive first results from the complete dose-finding part of a phase Ib/II study of tumor-agnostic NBTXR3 (PEP503) activated by radiotherapy with concurrent chemotherapy for pati
Read more →NBTXNANOBIOTIX ANNOUNCES KEY DEVELOPMENT MILESTONES FOR 2021 AFTER SUCCESSFUL NASDAQ INITIAL PUBLIC OFFERING Nanobiotix will use a portion of the proceeds from the its IPO to launch its global phase III registr
NANOBIOTIX ANNOUNCES KEY DEVELOPMENT MILESTONES FOR 2021 AFTER SUCCESSFUL NASDAQ INITIAL PUBLIC OFFERING "Following the successful closing of our initial public offering on Nasdaq in December 2020, Nanobiotix is well positioned to continue global development of NBTXR3 as planned
Read more →NBTXNanobiotix announces publication of phase III Soft Tissue Sarcoma data for first-in-class NBTXR3 in the Lancet Oncology
NANOBIOTIX ANNOUNCES PUBLICATION OF PHASE III SOFT TISSUE SARCOMA DATA FOR FIRST-IN-CLASS NBTXR3 IN THE LANCET ONCOLOGY Previously reported data from the registration study (Act.In.Sarc) in advanced Soft Tissue Sarcoma (STS) patients demonstrated a significant advantage in both
Read more →NBTXNanobiotix announces new organizational structure as the company enters its next stage after first european market approval
NANOBIOTIX ANNOUNCES NEW ORGANIZATIONAL STRUCTURE AS THE COMPANY ENTERS ITS NEXT STAGE AFTER FIRST EUROPEAN MARKET APPROVAL Recently appointed Chief Medical Officer (CMO) Edwina Baskin-Bey, M.D., will join the Executive Board Anne-Juliette Hermant, M.A., will be appointed Chief
Read more →NBTXNANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL
NANOBIOTIX APPOINTS NEW CHIEF MEDICAL OFFICER AS THE COMPANY EVOLVES AFTER ACHIEVEMENT OF EUROPEAN MARKET APPROVAL Biopharmaceutical veteran Edwina Baskin-Bey, M.D., joins Nanobiotix as its new Chief Medical Officer (CMO) Dr. Baskin-Bey will leverage her expertise in medical st
Read more →NBTXNanobiotix announces the launch of curadigm : a new nanotechnology platform for healthcare
NANOBIOTIX ANNOUNCES THE LAUNCH OF CURADIGM: A NEW NANOTECHNOLOGY PLATFORM FOR HEALTHCARE Curadigm opens new growth pathways for Nanobiotix beyond oncology, built on the success and know-how established through the development of NBTXR3 Curadigm will operate as a wholly-owned s
Read more →NBTXNANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES
NANOBIOTIX RAISES APPROXIMATELY EUR 29.5 MILLION IN PLACEMENT OF ORDINARY NEW SHARES Funds raised through an accelerated bookbuild offering announced on April 8, 2019 Placement follows announcement of the first European market approval for its lead product Hensify® Reinforces
Read more →NBTXNANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING
NANOBIOTIX LAUNCHES A CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING Paris, France, April 8, 2019 – NANOBIOTIX (the “Company”) (Euronext: NANO – ISIN: FR0011341205), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, inten
Read more →NBTXNanobiotix Announces First Ever Radioenhancer to Receive European Market Approval
NANOBIOTIX ANNOUNCES FIRST EVER RADIOENHANCER TO RECEIVE EUROPEAN MARKET APPROVAL Hensify®(NBTXR3) received European market approval (CE mark) enabling commercialization in 27 European Union countries for the treatment of locally advanced soft tissue sarcoma Hensify®--a first-i
Read more →NBTXNanobiotix announces its clinical registration plan in Head and Neck cancers for the United States following FDA feedback
Moving forward with Overall Survival (OS)-based, randomized, event-driven clinical trial for the United States Pre-IND feedback from US Food and Drug Administration (FDA) provides clarity to Nanobiotix on US regulatory pathway to approval Clinical trial authorization process to
Read more →NBTXNanobiotix 2018 Annual Results
Paris, France and Cambridge, Massachusetts, USA, March 15, 2019 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205 – the “Company”), a clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announced its unaudited1 consolidated results for
Read more →NBTXNanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank
Nanobiotix receives €14 million through the second tranche disbursement of financing from the European Investment Bank Proceeds strengthen balance sheet and cash visibility Payment triggered by the achievement of 2 key company milestones: Determination of the recommended dose a
Read more →NBTXNanobiotix Plans to Conduct Registered Public Offering in the United States
Nanobiotix Plans to Conduct Registered Public Offering in the United States Paris, France and Cambridge, Massachusetts (USA), January 16, 2019 – NANOBIOTIX SA (Euronext : NANO – ISIN : FR0011341205) announced today that it plans to conduct a registered public offering of its or
Read more →NBTXNanobiotix and MD Anderson Cancer Center announce a large-scale, comprehensive clinical collaboration on NBTXR3
Collaboration will initially support nine new phase I/II clinical trials with Nanobiotix’s first-in-class agent NBTXR3 for use in treating six cancer types - head and neck, pancreatic, thoracic, lung, gastrointestinal and genitourinary cancers - involving around 340 patients Mos
Read more →NBTXNanobiotix revenues for the 3rd quarter of 2018
Paris, France and Cambridge, Massachusetts, USA, November 15, 2018 – NANOBIOTIX (Euronext: NANO – ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its unaudited revenues for the third quarter of
Read more →NBTXNANOBIOTIX: Positive phase II/III results for NBTXR3 in Soft Tissue Sarcoma presented at ESMO
NANOBIOTIX: POSITIVE PHASE II/III RESULTS FOR NBTXR3 IN SOFT TISSUE SARCOMA PRESENTED AT ESMO Dr. Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie - Paris, presented first-in-class NBTXR3 positive Phase II/III results during the Sarcoma Proffered
Read more →NBTXNanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank
Nanobiotix receives first tranche disbursement of 16 million euros financing from European Investment Bank Proceeds will be used to speed up development of pioneering lead product NBTXR3 and to support the European go-to-market strategy Paris, France and Cambridge, Massachusett
Read more →NBTXNanobiotix to present positive results from its phase II/III clinical trial of NBTXR3 in patients with Soft Tissue Sarcoma (STS) and other ongoing phase I/II trials at upcoming ESMO and ASTRO annual conferences
NANOBIOTIX TO PRESENT POSITIVE RESULTS FROM ITS PHASE II/III CLINICAL TRIAL OF NBTXR3 IN PATIENTS WITH SOFT TISSUE SARCOMA (STS) AND OTHER ONGOING PHASE I/II TRIALS AT UPCOMING ESMO AND ASTRO ANNUAL CONFERENCES Dr. Sylvie Bonvalot will present positive results from its Phase II/
Read more →NBTXNanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018
Nanobiotix: Update on Head and Neck Phase I/II Trial with NBTXR3 and Other program data presented at ImmunoRad 2018 Strengthening of NBTXR3 data showing the potential impact on survival in elderly and frail patients with locally advanced head and neck cancers Biomarker analysis
Read more →NBTXNANOBIOTIX half year results for the six months ended June 30, 2018
Accessibility: Skip TopNav NANOBIOTIX half year results for the six months ended June 30, 2018 September 04, 2018 12:19 ET Nanobiotix half year results for the six months ended June 30, 2018 Major milestones achieved with the success of Soft Tissue Sarcoma phase III clinical
Read more →NBTXNANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment Bank
Accessibility: Skip TopNav NANOBIOTIX signs a 40 M€ non-dilutive financing agreement with the European Investment Bank July 26, 2018 12:30 ET NANOBIOTIX SIGNS A 40 M€ NON-DILUTIVE FINANCING AGREEMENT WITH THE EUROPEAN INVESTMENT BANK Acceleration of company's priorities in h
Read more →NBTXNANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3
Accessibility: Skip TopNav NANOBIOTIX announces positive phase II/III topline data in soft tissue sarcoma with NBTXR3 June 21, 2018 13:40 ET NANOBIOTIX ANNOUNCES POSITIVE PHASE II/III TOPLINE DATA IN SOFT TISSUE SARCOMA WITH NBTXR3 Trial achieved its primary endpoint of path
Read more →NBTXNANOBIOTIX' Management statement on recent share price variation
Accessibility: Skip TopNav NANOBIOTIX' Management statement on recent share price variation June 06, 2018 09:54 ET NANOBIOTIX' MANAGEMENT STATEMENT ON RECENT SHARE PRICE VARIATION Paris, France and Cambridge, Massachusetts, USA, June 6 2018 - NANOBIOTIX (Euronext: NANO - ISIN
Read more →NBTXNanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers
Accessibility: Skip TopNav Nanobiotix partners with Weill Cornell Medicine on pre-clinical studies to evaluate the impact of NBTXR3 on cGAS-STING pathway in mammary cancers May 03, 2018 13:34 ET NANOBIOTIX PARTNERS WITH WEILL CORNELL MEDICINE ON PRE-CLINICAL STUDIES TO EVALUA
Read more →NBTXNANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB
Accessibility: Skip TopNav NANOBIOTIX : THE UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER AND NANOBIOTIX HAVE AN AGREEMENT TO RUN IMMUNOTHERAPEUTIC PRE-CLINICAL RESEARCH IN LUNG CANCER COMBINING NBTXR3 AND NIVOLUMAB April 10, 2018 14:41 ET THE UNIVERSITY OF TEXAS MD ANDERSON C
Read more →NBTXNANOBIOTIX : Nanobiotix 2017 Annual Results
Nanobiotix 2017 Annual Results Paris, France and Cambridge, Massachusetts, USA, March 30, 2018 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering new approaches to the treatment of cancer, today announces its audited consoli
Read more →NBTXNANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting
Accessibility: Skip TopNav NANOBIOTIX presents first promising data from Phase I/II Liver Cancers trial of NBTXR3 at the American Society Of Clinical Oncology Gastrointestinal Annual Meeting January 22, 2018 02:01 ET NANOBIOTIX PRESENTS FIRST PROMISING DATA FROM PHASE I/II LIV
Read more →NBTXNANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers
Accessibility: Skip TopNav NANOBIOTIX partners with the Providence Cancer Institute to run immunotherapeutic preclinical research in pancreatic cancers January 11, 2018 02:07 ET NANOBIOTIX PARTNERS WITH THE PROVIDENCE CANCER INSTITUTE TO RUN IMMUNOTHERAPEUTIC PRECLINICAL RESEA
Read more →NBTXNANOBIOTIX : 2017 review and 2018 expected milestones
Nanobiotix: 2017 review and 2018 expected milestones Paris, France and Cambridge, Massachusetts, USA, December 26, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, t
Read more →NBTXNANOBIOTIX : FDA approves Nanobiotix's first Immuno-Oncology trial
FDA APPROVES NANOBIOTIX'S FIRST IMMUNO-ONCOLOGY TRIAL: A PHASE I/II STUDY OF NBTXR3 ACTIVATED BY RADIATION THERAPY (SABR) FOR PATIENTS WITH NON-SMALL CELL LUNG CANCER OR HEAD AND NECK SQUAMOUS CELL CARCINOMA CANCER TREATED WITH AN ANTI-PD1 ANTIBODY (NIVOLUMAB OR PEMBROLIZUMAB)
Read more →NBTXNANOBIOTIX presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting
Nanobiotix presented new clinical and pre-clinical data confirming NBTXR3's significant potential role in Immuno-Oncology at SITC Annual Meeting NBTXR3 activated by radiotherapy induces a significant adaptive immune pattern versus radiotherapy alone in patients with soft tissue
Read more →NBTXNANOBIOTIX provides update on the global development of its lead product NBTXR3
Accessibility: Skip TopNav NANOBIOTIX provides update on the global development of its lead product NBTXR3 November 09, 2017 14:14 ET Nanobiotix provides update on the global development of its lead product NBTXR3 Nanobiotix will give two immuno-oncology presentations at the
Read more →NBTXNANOBIOTIX successfully completes approximately eur 27.2 million placement of new shares
Accessibility: Skip TopNav NANOBIOTIX successfully completes approximately eur 27.2 million placement of new shares October 31, 2017 03:00 ET NANOBIOTIX SUCCESSFULLY COMPLETES APPROXIMATELY EUR 27.2 MILLION PLACEMENT OF NEW SHARES Funds raised via an accelerated book building
Read more →NBTXNANOBIOTIX launches capital increase by means of an accelerated bookbuild offering
Accessibility: Skip TopNav NANOBIOTIX launches capital increase by means of an accelerated bookbuild offering October 30, 2017 12:47 ET NANOBIOTIX LAUNCHES CAPITAL INCREASE BY MEANS OF AN ACCELERATED BOOKBUILD OFFERING Paris, France and Cambridge, Massachusetts, October 30, 2
Read more →NBTXNANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma
Accessibility: Skip TopNav NANOBIOTIX completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma October 23, 2017 02:00 ET Nanobiotix completes patient inclusion for Phase II/III trial of NBTXR3 in soft tissue sarcoma Paris, France and Cambridge, Mass
Read more →NBTXNANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S.
Accessibility: Skip TopNav NANOBIOTIX plans to conduct its first clinical trial with NBTXR3 in combination with immune checkpoint inhibitors in the U.S. September 28, 2017 12:29 ET Nanobiotix plans to conduct its first clinical trial with NBTXR3 in combination with immune chec
Read more →NBTXNANOBIOTIX half year results for the six months ended 30 June 2017
Accessibility: Skip TopNav NANOBIOTIX half year results for the six months ended 30 June 2017 August 31, 2017 13:29 ET Nanobiotix half year results for the six months Paris, France and Cambridge, Massachusetts, USA, August 31, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR00113
Read more →NBTXNANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop
Accessibility: Skip TopNav NANOBIOTIX : new translational data presented at ASTRO, NCI AND SITC'S Immunotherapy Workshop June 15, 2017 15:43 ET NANOBIOTIX: NEW TRANSLATIONAL DATA PRESENTED AT ASTRO, NCI AND SITC'S IMMUNOTHERAPY WORKSHOP Translational data showing tumor immune
Read more →NBTXNANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting
Accessibility: Skip TopNav NANOBIOTIX : promising data from phase I/II Head and Neck cancer trial with NBTXR3 presented at the American Society of Clinical Oncology's Annual Meeting June 05, 2017 12:00 ET NANOBIOTIX: PROMISING DATA FROM PHASE I/II HEAD AND NECK CANCER TRIAL
Read more →NBTXNANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-Oncology
Accessibility: Skip TopNav NANOBIOTIX announces first positive Human data showing that NBTXR3 could become a backbone in Immuno-Oncology May 18, 2017 01:58 ET NANOBIOTIX ANNOUNCES FIRST POSITIVE HUMAN DATA SHOWING THAT NBTXR3 COULD BECOME A BACKBONE IN IMMUNO-ONCOLOGY Biomark
Read more →NBTXNANOBIOTIX : 2016 Annual Results
Accessibility: Skip TopNav NANOBIOTIX : 2016 Annual Results April 28, 2017 12:00 ET Nanobiotix: 2016 Annual Results Paris, France and Cambridge, Massachusetts, USA, April 28, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company p
Read more →NBTXNANOBIOTIX successfully completes approx. EUR 25.1 million private placement of new shares
Accessibility: Skip TopNav NANOBIOTIX successfully completes approx. EUR 25.1 million private placement of new shares April 07, 2017 02:42 ET Not for release, publication or distribution, directly or indirectly, in or into the United States, Canada, Australia or Japan. NANOBI
Read more →NBTXNANOBIOTIX : Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO
Accessibility: Skip TopNav NANOBIOTIX : Nanobiotix expands its clinical development in Head and Neck cancer and Immuno-Oncology ; new clinical data to be presented at ASCO April 04, 2017 02:35 ET NANOBIOTIX EXPANDS ITS CLINICAL DEVELOPMENT IN HEAD AND NECK CANCER AND IMMUNO-ON
Read more →NBTXNANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma
Accessibility: Skip TopNav NANOBIOTIX: the Independent Data Monitoring Committee recommends the continuation of the ongoing phase II/III trial of NBTXR3 in Soft Tissue Sarcoma March 23, 2017 13:15 ET NANOBIOTIX: THE INDEPENDENT DATA MONITORING COMMITTEE RECOMMENDS THE CONTINU
Read more →NBTXNANOBIOTIX : Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017
Accessibility: Skip TopNav NANOBIOTIX : Nanobiotix to present preclinical data on nanoparticle radioenhancer NBTXR3 at the AACR Annual Meeting 2017 March 07, 2017 02:39 ET NANOBIOTIX TO PRESENT PRECLINICAL DATA ON NANOPARTICLE RADIOENHANCER NBTXR3 AT THE AACR ANNUAL MEETING 2
Read more →NBTXNANOBIOTIX appoints senior executive from pharmaceutical industry, as Chief Operating Officer
Accessibility: Skip TopNav NANOBIOTIX appoints senior executive from pharmaceutical industry, as Chief Operating Officer February 07, 2017 02:19 ET Nanobiotix appoints senior executive from pharmaceutical industry, as Chief Operating Officer Oncology industry veteran to overs
Read more →NBTXNANOBIOTIX : 2016 review and 2017 anticipated milestones
Accessibility: Skip TopNav NANOBIOTIX : 2016 review and 2017 anticipated milestones January 31, 2017 14:31 ET Nanobiotix: 2016 review and 2017 anticipated milestones Paris, France and Cambridge, Massachusetts, USA, January 31, 2017 - NANOBIOTIX (Euronext: NANO - ISIN: FR00113
Read more →NBTXNANOBIOTIX reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial
Accessibility: Skip TopNav NANOBIOTIX reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers trial December 14, 2016 12:30 ET Nanobiotix reports positive Phase I/II preliminary data on feasibility and safety of NBTXR3 in liver cancers
Read more →NBTXNANOBIOTIX Provides Update on Global Development of Lead Product NBTXR3
Accessibility: Skip TopNav NANOBIOTIX Provides Update on Global Development of Lead Product NBTXR3 November 28, 2016 13:58 ET Nanobiotix Provides Update on Global Development of Lead Product NBTXR3 Seven clinical trials across the world More than 2/3 of STS patients recruit
Read more →NBTXNANOBIOTIX presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Cancer Annual Meeting
Accessibility: Skip TopNav NANOBIOTIX presents NBTXR3 preclinical data demonstrating its potential usage as in situ vaccine for cancer at the Society for Immunotherapy of Cancer Annual Meeting November 14, 2016 02:01 ET NANOBIOTIX PRESENTS NBTXR3 PRECLINICAL DATA DEMONSTRATING
Read more →NBTXNanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia
Accessibility: Skip TopNav Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia October 20, 2016 15:43 ET Nanobiotix's partner, PharmaEngine, has launched a new NBTXR3 clinical trial in head and neck cancers in Asia Sev
Read more →NBTXNANOBIOTIX Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations
Accessibility: Skip TopNav NANOBIOTIX Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development and Director of Investor Relations October 03, 2016 15:25 ET Nanobiotix Strengthens U.S. leadership with appointments of Head of U.S. Clinical Development
Read more →NBTXNanobiotix announces submission for first market approval of lead product NBTXR3 in Europe
Accessibility: Skip TopNav Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe September 13, 2016 17:30 ET Nanobiotix announces submission for first market approval of lead product NBTXR3 in Europe CE Mark filing based on current level o
Read more →NBTXNanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer
Accessibility: Skip TopNav Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer July 06, 2016 13:16 ET Nanobiotix reports successful results from Phase I/II Trial of NBTXR3 in Head & Neck Cancer Primary safety and feasibility endpoints a
Read more →NBTXNanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology
Accessibility: Skip TopNav Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology May 31, 2016 02:00 ET Small but heading for the big time Nanobiotix establishes promising preclinical proof-of-concept in Immuno Oncology Paris, France, Cambridge, MA,
Read more →NBTXNanobiotix: 2015 Annual Results
Accessibility: Skip TopNav Nanobiotix: 2015 Annual Results April 29, 2016 13:30 ET Small but heading for the big time Nanobiotix: 2015 Annual Results Paris, Cambridge, April 29, 2016 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine compa
Read more →NBTXNANOBIOTIX : Nanobiotix completes a EUR 21.3 million private placement of new ordinary shares
Accessibility: Skip TopNav NANOBIOTIX : Nanobiotix completes a EUR 21.3 million private placement of new ordinary shares March 11, 2016 11:40 ET Small but heading for the big time NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STAT
Read more →NBTXNanobiotix starts a new research program, in Immuno Oncology, with its lead product NBTXR3
Accessibility: Skip TopNav Nanobiotix starts a new research program, in Immuno Oncology, with its lead product NBTXR3 January 05, 2016 02:19 ET Small but heading for the big time Nanobiotix starts a new research program, in Immuno Oncology, with its lead product NBTXR3 Paris
Read more →NBTXNANOBIOTIX : FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer
Accessibility: Skip TopNav NANOBIOTIX : FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostate cancer January 04, 2016 01:30 ET Small but heading for the big time FDA approved Investigational New Drug for NBTXR3 in a new clinical study in prostat
Read more →NBTXNanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened
Accessibility: Skip TopNav Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically as planned: already 7 countries and 29 sites opened November 13, 2015 02:00 ET Small but heading for the big time Nanobiotix's Soft Tissue Sarcoma pivotal trial expands dynamically a
Read more →NBTXNANOBIOTIX: starts Phase I/II clinical trial in liver Metastasis and Hepatocellular Cancer with its lead product NBTXR3
PARIS, July 1, 2015 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO), a late clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, has been authorized to begin a new clinical trial in liver cancers for its lead NanoXray product, NBTXR3.
Read more →NBTXNANOBIOTIX :reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3
Accessibility: Skip TopNav NANOBIOTIX :reports positive preliminary results in Head and Neck cancer Phase I/II clinical trial with NBTXR3 June 10, 2015 03:06 ET Small but heading for the big time Nanobiotix reports positive preliminary results in Head and Neck cancer Phase I/
Read more →NBTXNANOBIOTIX : 2014 ANNUAL RESULTS
Accessibility: Skip TopNav NANOBIOTIX : 2014 ANNUAL RESULTS April 14, 2015 12:03 ET Small but heading for the big time Nanobiotix: 2014 Annual Results Paris, France, 14 April, 2015 - NANOBIOTIX (Euronext: NANO - ISIN: FR0011341205), a late clinical-stage nanomedicine company
Read more →NBTXNanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe
Accessibility: Skip TopNav Nanobiotix receives first approval to start phase II/III registration trial in soft tissue sarcoma in Europe October 16, 2014 02:00 ET Small but heading for the big time Nanobiotix receives first approval to start phase II/III registration trial in
Read more →NBTXNanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO
Accessibility: Skip TopNav Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO June 02, 2014 01:51 ET Small but heading for the big time Nanobiotix presents successful Phase I results for its lead nanomedicine product NBTXR3 at ASCO
Read more →NBTXNANOBIOTIX: sees Clinical Advance in Soft Tissue Sarcoma Pilot Trial with Lead Product, NBTXR3 Market Development Plan Outlined For Earlier Potential Launch in 2016
Small but heading for the big time PARIS, Feb. 10, 2014 (GLOBE NEWSWIRE) -- NANOBIOTIX (Euronext: NANO), a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer, announces today its development plan for the CE marking of NBTXR3, the fi
Read more →NBTXNANOBIOTIX :strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar
Accessibility: Skip TopNav NANOBIOTIX :strengthens its NanoXray pipeline with the launch of NBTX-TOPO development, the first nanotherapeutic with embedded radar December 06, 2013 02:00 ET Small but heading for a big time Paris, France, 6 December, 2013 - NANOBIOTIX (Euronext:
Read more →NBTXNANOBIOTIX strengthens its management team
The Company, based in Paris, France. has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. Laurent Levy, CEO and co-founder of Nanobiotix, is the Vice-President of the European Technology Platform of Nanomedicine (ETPN). For more inform
Read more →NBTXNANOBIOTIX : Half Year Results for the period ended 30 June 2013
The Company is based in Paris, France. Nanobiotix is listed on the NYSE Euronext regulated market in Paris (ISIN: FR0011341205, Euronext ticker: NANO, Bloomberg: NANO: FP). www.nanobiotix.com For more information, please contact: Nanobiotix Sarah Gaubert Head of Communication and
Read more →NBTXNanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication
Accessibility: Skip TopNav Nanobiotix announces €2.8 million grant from bpifrance to accelerate development of NBTXR3 in a third new indication July 03, 2013 12:35 ET Through ETPN (European Technology Platform of Nanomedicine), Nanobiotix is driving nanomedicine in Europe and
Read more →NBTXNanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the National Cancer Institute for development
Accessibility: Skip TopNav Nanobiotix announces the selection of its second NanoXray product, NBTX-IV and a collaboration with the National Cancer Institute for development June 26, 2013 02:00 ET Characterization studies to be undertaken by the US National Cancer Institute's N
Read more →NBTXNanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3
Accessibility: Skip TopNav Nanobiotix receives approval from ANSM to start new Clinical Trial with Lead Product NBTXR3 June 13, 2013 02:00 ET Second indication for NanoXray product in Head and Neck cancer patients Paris, France, June 13, 2013 - NANOBIOTIX (Euronext: NANO), a
Read more →NBTXNanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma
Accessibility: Skip TopNav Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma June 03, 2013 07:12 ET Nanobiotix's NBTXR3 Achieves Clinical Milestone Reaching Proof-Of-Concept in Phase I Trial of Soft Tissue Sarcoma
Read more →Competitive Position
How NBTX ranks across every disease it competes inCompetitive Position is a premium feature
See how NBTX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial